BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lip GY, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L. Antithrombotic Therapy for Atrial Fibrillation. Chest 2018;154:1121-201. [DOI: 10.1016/j.chest.2018.07.040] [Cited by in Crossref: 397] [Cited by in F6Publishing: 344] [Article Influence: 99.3] [Reference Citation Analysis]
Number Citing Articles
1 Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, Sharan L, Allen LaPointe NM, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski A, Al-Khatib SM, Sanders GD. Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. Thromb Haemost 2018;118:2171-87. [PMID: 30376678 DOI: 10.1055/s-0038-1675400] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 20.5] [Reference Citation Analysis]
2 Stoica MC, Gáll Z, Gliga ML, Căldăraru CD, Székely O. Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease. Medicina (Kaunas) 2021;57:422. [PMID: 33925501 DOI: 10.3390/medicina57050422] [Reference Citation Analysis]
3 Muria-Subirats E, Clua-Espuny JL, Ballesta-Ors J, Lorman-Carbo B, Lechuga-Duran I, Fernández-Saez J, Pla-Farnos R, On Behalf Members Of Africat Group. Incidence and Risk Assessment for Atrial Fibrillation at 5 Years: Hypertensive Diabetic Retrospective Cohort. Int J Environ Res Public Health 2020;17:E3491. [PMID: 32429492 DOI: 10.3390/ijerph17103491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Kanjee Z, McCann ML, Freed JA. Availability of Specific Direct Oral Anticoagulant Reversal Agents in US Hospitals. JAMA Netw Open 2021;4:e2110079. [PMID: 33988710 DOI: 10.1001/jamanetworkopen.2021.10079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Krittayaphong R, Boonyapiphat T, Wongvipaporn C, Sairat P; COOL-AF Investigators. Age-Related Clinical Outcomes of Patients with Non-Valvular Atrial Fibrillation: Insights from the COOL-AF Registry. Clin Interv Aging 2021;16:707-19. [PMID: 33953549 DOI: 10.2147/CIA.S302389] [Reference Citation Analysis]
6 Zhang C, Pan MM, Wang N, Wang WW, Li Z, Gu ZC, Lin HW. Feasibility and usability of a mobile health tool on anticoagulation management for patients with atrial fibrillation: a pilot study. Eur J Clin Pharmacol 2021. [PMID: 34671819 DOI: 10.1007/s00228-021-03236-4] [Reference Citation Analysis]
7 Ding WY, Lip GY, Gupta D. Left Atrial Appendage Occlusion—A Choice or a Last Resort? How to Approach the Patient. Interventional Cardiology Clinics 2022. [DOI: 10.1016/j.iccl.2021.11.006] [Reference Citation Analysis]
8 Kozieł M, Teutsch C, Bayer V, Lu S, Gurusamy VK, Halperin JL, Rothman KJ, Diener HC, Ma CS, Huisman MV, Lip GYH; GLORIA‐AF Investigators. Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world. J Arrhythm 2021;37:990-1006. [PMID: 34386125 DOI: 10.1002/joa3.12588] [Reference Citation Analysis]
9 Gebreyohannes EA, Salter S, Chalmers L, Bereznicki L, Lee K. Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence. Am J Cardiovasc Drugs 2021;21:419-33. [PMID: 33369718 DOI: 10.1007/s40256-020-00457-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
10 Brokmeier H, Kido K. Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary Hypertension-a Systematic Review. Ann Pharmacother 2021;55:995-1009. [PMID: 33148014 DOI: 10.1177/1060028020970618] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Antman EM, Braunwald E, Giugliano RP. Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Thromb Haemost 2021;121:140-9. [PMID: 32920808 DOI: 10.1055/s-0040-1716540] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Matsushima K, Leichtle SW, Wild J, Young K, Chang G, Demetriades D; EAST ACT-TBI Multicenter Study Group. Anticoagulation therapy in patients with traumatic brain injury: An Eastern Association for the Surgery of Trauma multicenter prospective study. Surgery 2021;169:470-6. [PMID: 32928573 DOI: 10.1016/j.surg.2020.07.040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Boriani G, Vitolo M, Imberti JF, Potpara TS, Lip GYH. What do we do about atrial high rate episodes? Eur Heart J Suppl 2020;22:O42-52. [PMID: 33380943 DOI: 10.1093/eurheartj/suaa179] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
14 Lin Y, Xiong H, Su J, Lin J, Zhou Q, Lin M, Zhao W, Peng F. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation. Heart Vessels 2022. [PMID: 35041061 DOI: 10.1007/s00380-022-02021-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Peck KA, Ley EJ, Brown CV, Moore EE, Sava JA, Ciesla DJ, Sperry JL, Rizzo AG, Rosen NG, Brasel KJ, Kozar R, Inaba K, Martin MJ. Early anticoagulant reversal after trauma: A Western Trauma Association critical decisions algorithm. J Trauma Acute Care Surg 2021;90:331-6. [PMID: 33055578 DOI: 10.1097/TA.0000000000002979] [Reference Citation Analysis]
16 Lomakina V, Sozio SJ, Tekle J. Use of Apixaban in Atrial Fibrillation With Ritonavir-Boosted Antiretroviral Therapy: A Case Report. J Pharm Pract 2022;:8971900221074938. [PMID: 35138967 DOI: 10.1177/08971900221074938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ghia S, Mehta D, Bhatt HV. Device-Detected Subclinical Atrial Fibrillation: The Anesthesiologist's Perspective. J Cardiothorac Vasc Anesth 2020;34:2876-80. [PMID: 32690237 DOI: 10.1053/j.jvca.2020.05.036] [Reference Citation Analysis]
18 Kotalczyk A, Gue YX, Potpara TS, Lip GYH. Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon? Expert Opin Pharmacother 2021;22:1061-70. [PMID: 33491506 DOI: 10.1080/14656566.2021.1879050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Boriani G, Healey JS, Schnabel RB, Lopes RD, Calkins H, Camm JA, Freedman B. Oral anticoagulation for subclinical atrial tachyarrhythmias detected by implantable cardiac devices: an international survey of the AF-SCREEN Group. International Journal of Cardiology 2019;296:65-70. [DOI: 10.1016/j.ijcard.2019.07.039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
20 Chan YH, Lee HF, Li PR, Liu JR, Chao TF, Wu LS, Chang SH, Yeh YH, Kuo CT, See LC, Lip GYH. Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. Cardiovasc Diabetol 2020;19:63. [PMID: 32404168 DOI: 10.1186/s12933-020-01043-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
21 Nielsen PB, Larsen TB, Skjøth F, Søgaard M, Lip GYH. Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. Eur Heart J Cardiovasc Pharmacother 2021;7:31-9. [PMID: 31774504 DOI: 10.1093/ehjcvp/pvz070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
22 Ferguson C, Lowres N, Freedman B. Stroke Risk in Adults With Atrial Fibrillation According to Sex. Heart Lung Circ 2021;30:937-8. [PMID: 33896707 DOI: 10.1016/j.hlc.2021.04.006] [Reference Citation Analysis]
23 Luo CF, Mo P, Li GQ, Liu SM. Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis. Eur Heart J Cardiovasc Pharmacother 2021;7:218-24. [PMID: 32129850 DOI: 10.1093/ehjcvp/pvaa016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Fang MC. Social Determinants of Health, Income, and Anticoagulation Outcomes. J Am Coll Cardiol 2022;79:2514-5. [PMID: 35738712 DOI: 10.1016/j.jacc.2022.04.028] [Reference Citation Analysis]
25 Kneihsl M, Bisping E, Scherr D, Mangge H, Fandler-Höfler S, Colonna I, Haidegger M, Eppinger S, Hofer E, Fazekas F, Enzinger C, Gattringer T. Predicting atrial fibrillation after cryptogenic stroke via a clinical risk score-a prospective observational study. Eur J Neurol 2022;29:149-57. [PMID: 34519135 DOI: 10.1111/ene.15102] [Reference Citation Analysis]
26 Roldán V, Martínez-montesinos L, López-gálvez R, García-tomás L, Lip GYH, Rivera-caravaca JM, Marín F. Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. JPM 2022;12:487. [DOI: 10.3390/jpm12030487] [Reference Citation Analysis]
27 Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, Guo Y, Sriratanasathavorn C, Oh S, Okumura K, Lip GYH. 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. J Arrhythm 2021;37:1389-426. [PMID: 34887945 DOI: 10.1002/joa3.12652] [Reference Citation Analysis]
28 Schwab K, Smith R, Wager E, Kaur S, Alvarez L, Wagner J, Leung H. Identification and early anticoagulation in patients with atrial fibrillation in the emergency department. Am J Emerg Med 2021;44:315-22. [PMID: 32331958 DOI: 10.1016/j.ajem.2020.04.019] [Reference Citation Analysis]
29 O'Shea RS, Davitkov P, Ko CW, Rajasekhar A, Su GL, Sultan S, Allen AM, Falck-Ytter Y. AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology 2021;161:1615-1627.e1. [PMID: 34579936 DOI: 10.1053/j.gastro.2021.08.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Negreva MN, Prodanova KS, Vitlianova KD. Paroxysmal atrial fibrillation is associated with early coagulation activity regardless of risk factors for embolism. Minerva Cardiol Angiol 2021;69:269-76. [PMID: 32657551 DOI: 10.23736/S2724-5683.20.05209-3] [Reference Citation Analysis]
31 Gumprecht J, Domek M, Lip GYH, Shantsila A. Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management. J Hum Hypertens 2019;33:824-36. [DOI: 10.1038/s41371-019-0279-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
32 Chao TF, Chen SA, Lip GYH. Recommendations on stroke prevention for patients having a CHA2DS2-VASc score of 1 (males) or 2 (females) in 2019 atrial fibrillation guidelines. Trends Cardiovasc Med 2019;29:427-8. [PMID: 30833072 DOI: 10.1016/j.tcm.2019.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Anouassi Z, Atallah B, Alsoud LO, El Nekidy W, Al Mahmeed W, AlJaabari M, Almuti K. Appropriateness of the Direct Oral Anticoagulants Dosing in the Middle East Gulf Region. J Cardiovasc Pharmacol 2021;77:182-8. [PMID: 32925474 DOI: 10.1097/FJC.0000000000000913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Wang TF, Carrier M. How I treat obese patients with oral anticoagulants. Blood 2020;135:904-11. [PMID: 31978224 DOI: 10.1182/blood.2019003528] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
35 Lee S, Choi E, Kwon S, Jung J, Han K, Cha M, Oh S, Lip GY. Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use. Circ: Cardiovascular Quality and Outcomes 2020;13. [DOI: 10.1161/circoutcomes.119.005894] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Douketis JD, Syed S, Li N, Narouze S, Radwi M, Duncan J, Schulman S, Spyropoulos AC. A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant. Res Pract Thromb Haemost 2021;5:159-67. [PMID: 33537540 DOI: 10.1002/rth2.12430] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Rome BN, Gagne JJ, Avorn J, Kesselheim AS. Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study. Am Heart J 2021;233:109-21. [PMID: 33358690 DOI: 10.1016/j.ahj.2020.12.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
38 Rivera-Caravaca JM, Esteve-Pastor MA, Camelo-Castillo A, Ramírez-Macías I, Lip GYH, Roldán V, Marín F. Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. Expert Opin Pharmacother 2020;21:1867-81. [PMID: 32658596 DOI: 10.1080/14656566.2020.1789099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Le Mao R, Tromeur C, Couturaud F. A case of acute pulmonary embolism with severe haemoptysis. Thromb Res 2021:S0049-3848(21)00332-7. [PMID: 34045054 DOI: 10.1016/j.thromres.2021.05.011] [Reference Citation Analysis]
40 Intagliata NM, Davitkov P, Allen AM, Falck-Ytter YT, Stine JG. AGA Technical Review on Coagulation in Cirrhosis. Gastroenterology 2021;161:1630-56. [PMID: 34579937 DOI: 10.1053/j.gastro.2021.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Barletta JF, Erstad BL. Dosing Medications for Coagulopathy Reversal in Patients with Extreme Obesity. J Emerg Med 2022:S0736-4679(22)00307-9. [PMID: 35906122 DOI: 10.1016/j.jemermed.2022.04.036] [Reference Citation Analysis]
42 Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GY. ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. Am J Med 2019;132:856-61. [PMID: 30659810 DOI: 10.1016/j.amjmed.2019.01.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 16.0] [Reference Citation Analysis]
43 Kopin D, Jones WS, Klein A, Barnes GD. Anticoagulation and antiplatelet therapy in stable coronary artery disease: A multicenter survey. Thromb Res 2019;180:25-7. [PMID: 31170568 DOI: 10.1016/j.thromres.2019.05.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Essa H, Hill AM, Lip GYH. Atrial Fibrillation and Stroke. Card Electrophysiol Clin 2021;13:243-55. [PMID: 33516402 DOI: 10.1016/j.ccep.2020.11.003] [Reference Citation Analysis]
45 Oladiran O, Nwosu I. Stroke risk stratification in atrial fibrillation: a review of common risk factors. J Community Hosp Intern Med Perspect 2019;9:113-20. [PMID: 31044042 DOI: 10.1080/20009666.2019.1593781] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
46 Porter AL, Margolis AR, Staresinic CE, Nagy MW, Schoen RR, Ray CA, Fletcher CD. Feasibility and safety of a 12-week INR follow-up protocol over 2 years in an anticoagulation clinic: a single-arm prospective cohort study. J Thromb Thrombolysis 2019;47:200-8. [PMID: 30368762 DOI: 10.1007/s11239-018-1760-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Menichelli D, Del Sole F, Di Rocco A, Farcomeni A, Vestri A, Violi F, Pignatelli P, Lip GYH, Pastori D. Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. Eur Heart J Cardiovasc Pharmacother 2021;7:f11-9. [PMID: 33493255 DOI: 10.1093/ehjcvp/pvab002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
48 Chan YH, Lee HF, See LC, Tu HT, Chao TF, Yeh YH, Wu LS, Kuo CT, Chang SH, Lip GYH. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. Chest. 2019;156:529-543. [PMID: 31103697 DOI: 10.1016/j.chest.2019.04.108] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 17.3] [Reference Citation Analysis]
49 Chao TF, Chan YH, Chiang CE, Tuan TC, Liao JN, Chen TJ, Lip GYH, Chen SA. Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation. Clin Res Cardiol 2021. [PMID: 33704551 DOI: 10.1007/s00392-021-01816-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Gilbert BW, Dingman JS, Reeder JA, Le SM, Ponce PJ, Philip GJ. Does a dose relationship exist with prothrombin complex and factor Xa inhibitor reversal? An alternate perspective of Yohe et al. Am J Emerg Med 2020;38:686-7. [PMID: 31522926 DOI: 10.1016/j.ajem.2019.158431] [Reference Citation Analysis]
51 Lee SR, Choi EK, Park SH, Jung JH, Han KD, Oh S, Lip GYH. Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. Eur Heart J Cardiovasc Pharmacother 2021:pvab004. [PMID: 33471125 DOI: 10.1093/ehjcvp/pvab004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
52 Neira VM, Baghaffar A, Doggett N, Ke JXC, Stewart K. Coagulopathy Management of an Acute Type A Aortic Dissection in a Patient Taking Apixaban. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00270-6. [PMID: 33896711 DOI: 10.1053/j.jvca.2021.03.028] [Reference Citation Analysis]
53 van der Endt VHW, Milders J, Penning de Vries BBL, Trines SA, Groenwold RHH, Dekkers OM, Trevisan M, Carrero JJ, van Diepen M, Dekker FW, de Jong Y. Comprehensive comparison of stroke risk score performance: a systematic review and meta-analysis among 6 267 728 patients with atrial fibrillation. Europace 2022:euac096. [PMID: 35894866 DOI: 10.1093/europace/euac096] [Reference Citation Analysis]
54 Park S, Je NK. Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation. J Cardiovasc Pharmacol Ther 2021;26:656-64. [PMID: 34558337 DOI: 10.1177/10742484211049919] [Reference Citation Analysis]
55 Benipal H, Holbrook A, Paterson JM, Douketis J, Foster G, Ma J, Thabane L. Derivation and validation of predictors of oral anticoagulant-related adverse events in seniors transitioning from hospital to home. Thromb Res 2021;206:18-28. [PMID: 34391064 DOI: 10.1016/j.thromres.2021.07.016] [Reference Citation Analysis]
56 Bareka M, Ntalouka MP, Kolonia K, Koutalos AA, Hantes M, Arnaoutoglou E. Introducing the "Bleeding Team": Urgent Reconstruction of an Open Fracture in a Patient Receiving Acenocoumarol: A Case Report. JBJS Case Connect 2021;11. [PMID: 34166270 DOI: 10.2106/JBJS.CC.20.00786] [Reference Citation Analysis]
57 Park S, Je NK. Factors That Affect Time to Switch From Warfarin to a Direct Oral Anticoagulant After Change in the Reimbursement Criteria in Patients With Atrial Fibrillation. J Cardiovasc Pharmacol Ther 2020;25:57-64. [PMID: 31405298 DOI: 10.1177/1074248419868996] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Oyama K, Giugliano RP, Berg DD, Ruff CT, Jarolim P, Tang M, Murphy SA, Lanz HJ, Grosso MA, Antman EM, Braunwald E, Morrow DA. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Eur Heart J 2021;42:1698-706. [PMID: 33760027 DOI: 10.1093/eurheartj/ehab141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
59 Zhang J, Lenarczyk R, Marin F, Malaczynska-Rajpold K, Kosiuk J, Doehner W, Van Gelder IC, Lee G, Hendriks JM, Lip GYH, Potpara TS. The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. Europace 2021;23:314-22. [PMID: 33554259 DOI: 10.1093/europace/euaa358] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Smythe MA, Parker D, Garwood CL, Cuker A, Messé SR. Timing of Initiation of Oral Anticoagulation after Acute Ischemic Stroke in Patients with Atrial Fibrillation. Pharmacotherapy 2020;40:55-71. [PMID: 31698510 DOI: 10.1002/phar.2345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
61 Pallazola VA, Kapoor RK, Kapoor K, McEvoy JW, Blumenthal RS, Gluckman TJ. Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism: A clinical review. Vasc Med 2019;24:141-52. [PMID: 30755150 DOI: 10.1177/1358863X18819816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
62 Chao TF, Chan YH, Tuan TC, Liao JN, Chen TJ, Lip GYH, Chen SA. Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? a nationwide cohort study. Eur Heart J Qual Care Clin Outcomes 2021:qcab050. [PMID: 34302335 DOI: 10.1093/ehjqcco/qcab050] [Reference Citation Analysis]
63 Tittl L, Marten S, Naue C, Beyer-Westendorf J. 5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry. Thromb Res 2021;202:24-30. [PMID: 33711755 DOI: 10.1016/j.thromres.2021.03.004] [Reference Citation Analysis]
64 Vestal ML, Hodulik K, Mando-Vandrick J, James ML, Ortel TL, Fuller M, Notini M, Friedland M, Welsby IJ. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. J Thromb Thrombolysis 2021. [PMID: 34101050 DOI: 10.1007/s11239-021-02495-3] [Reference Citation Analysis]
65 Starr JA, Pinner NA, Mannis M, Stuart MK. A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease. Ann Pharmacother 2021;:10600280211040093. [PMID: 34459281 DOI: 10.1177/10600280211040093] [Reference Citation Analysis]
66 Milling TJ, Pollack CV. A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus? The American Journal of Emergency Medicine 2020;38:1890-903. [DOI: 10.1016/j.ajem.2020.05.086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
67 Bayer V, Kotalczyk A, Kea B, Teutsch C, Larsen P, Button D, Huisman MV, Lip GYH, Olshansky B. Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry. J Am Heart Assoc 2022;:e023907. [PMID: 35243870 DOI: 10.1161/JAHA.121.023907] [Reference Citation Analysis]
68 Huppertz N, Lip GYH, Lane DA. Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation. Clin Res Cardiol 2020;109:802-9. [PMID: 31701215 DOI: 10.1007/s00392-019-01567-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Negreva M, Zarkova A, Prodanova K, Petrov P. Paroxysmal Atrial Fibrillation: Insight Into the Intimate Mechanisms of Coagulation. Cardiol Res 2020;11:22-32. [PMID: 32095193 DOI: 10.14740/cr972] [Reference Citation Analysis]
70 Patil T, Hanna S, Torre W. A rare case report of apixaban-induced lichenoid eruption. Ther Adv Drug Saf 2020;11:2042098620937884. [PMID: 32874531 DOI: 10.1177/2042098620937884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Hariharan NN, Patel K, Sikder O, Perera KS, Diener H, Hart RG, Eikelboom JW. Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis. European Stroke Journal. [DOI: 10.1177/23969873221076971] [Reference Citation Analysis]
72 Zhu W, Ye Z, Chen S, Wu D, He J, Dong Y, Lip GYH, Liu C. Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients. Stroke 2021;52:1225-33. [PMID: 33596677 DOI: 10.1161/STROKEAHA.120.031007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Ng DL, Malik NMBA, Chai CS, Goh GM, Tan SB, Bee PC, Gan GG, Said AB. Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study. Health Qual Life Outcomes 2020;18:347. [PMID: 33081816 DOI: 10.1186/s12955-020-01600-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Rahme E, Godin R, Nedjar H, Dasgupta K, Tagalakis V. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. Thromb Res 2021;203:121-30. [PMID: 34000493 DOI: 10.1016/j.thromres.2021.05.005] [Reference Citation Analysis]
75 Ritchie LA, Lip GYH, Lane DA. Optimization of atrial fibrillation care: management strategies and quality measures. Eur Heart J Qual Care Clin Outcomes 2021;7:121-33. [PMID: 32761177 DOI: 10.1093/ehjqcco/qcaa063] [Reference Citation Analysis]
76 Krittayaphong R, Winijkul A, Kunjara-na-ayudhya R, Apiyasawat S, Siriwattana K, Kanjanarutjawiwat W, Dutsadeevettakul S, Lip GYH; for the COOL-AF Investigators. Adherence to Anticoagulant Guideline for Atrial Fibrillation Improves Outcomes in Asian Population: The COOL-AF Registry. Stroke 2020;51:1772-80. [DOI: 10.1161/strokeaha.120.029295] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
77 Mantis C, Alexopoulos D. Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner? Thromb Res 2019;176:133-9. [PMID: 30826397 DOI: 10.1016/j.thromres.2019.02.022] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Baang HY, Sheth KN. Stroke Prevention After Intracerebral Hemorrhage: Where Are We Now? Curr Cardiol Rep 2021;23:162. [PMID: 34599375 DOI: 10.1007/s11886-021-01594-0] [Reference Citation Analysis]
79 Abdel-Qadir H, Singh SM, Pang A, Austin PC, Jackevicius CA, Tu K, Dorian P, Ko DT. Evaluation of the Risk of Stroke Without Anticoagulation Therapy in Men and Women With Atrial Fibrillation Aged 66 to 74 Years Without Other CHA2DS2-VASc Factors. JAMA Cardiol 2021;6:918-25. [PMID: 34009232 DOI: 10.1001/jamacardio.2021.1232] [Reference Citation Analysis]
80 Ding WY, Rivera-Caravaca JM, Lip GYH. Letter by Ding et al Regarding Article, "Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation". Stroke 2020;51:e361-2. [PMID: 33226919 DOI: 10.1161/STROKEAHA.120.031780] [Reference Citation Analysis]
81 Kalarus Z, Svendsen JH, Capodanno D, Dan GA, De Maria E, Gorenek B, Jędrzejczyk-Patej E, Mazurek M, Podolecki T, Sticherling C, Tfelt-Hansen J, Traykov V, Lip GYH, Fauchier L, Boriani G, Mansourati J, Blomström-Lundqvist C, Mairesse GH, Rubboli A, Deneke T, Dagres N, Steen T, Ahrens I, Kunadian V, Berti S. Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). Europace 2019;21:1603-4. [PMID: 31353412 DOI: 10.1093/europace/euz163] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
82 Rodríguez de Santiago E, Sánchez Aldehuelo R, Riu Pons F, Rodríguez Escaja C, Fernández-Esparrach G, Cañete-Ruiz Á, Ferre Aracil C, Pérez-Corte D, Ríos León R, Marcos-Prieto HM, Delgado-Guillena PG, García-Rodríguez A, Guarner-Argente C, Muriel A, de la Fuente-Briongos E, García García de Paredes A, Parejo-Carbonell S, Téllez L, Senosiaín-Lalastra C, Burgos-Santamaría D, Aicart-Ramos M, Mateos Muñoz B, Peñas-García B, Pagano G, Casals Urquiza G, Urpi Ferreruela M, Ángel de Jorge-Turrión M, Barreiro-Alonso E, Fraile-López M, Gómez-Outomuro A, Altamirano MI, Núñez Esteban M, Ruiz-Andreu M, Arribas-Anta J, de Frutos D, Herreros-de-Tejada A, Arias-Rivera ML, Roldán-Fernández M, Marcos Martín ÁF, Zamora J, Vázquez-Sequeiros E, Albillos A; ENDOHEM research group of the Spanish Society of Gastrointestinal Endoscopy (SEED) and the Spanish Gastroenterology Association (AEG). Endoscopy-Related Bleeding and Thromboembolic Events in Patients on Direct Oral Anticoagulants or Vitamin K Antagonists. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31627-X. [PMID: 33279783 DOI: 10.1016/j.cgh.2020.11.037] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Kozieł M, Al-Saady N, Hjortshøj SP, Goudev A, Huber K, Cohen A, Jin J, Melino M, Winters SM, Goette A, Lip GYH. Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial. Clin Res Cardiol 2020;109:1018-24. [PMID: 31915996 DOI: 10.1007/s00392-019-01594-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Okutucu S, Görenek B. Review of the 2019 European Society of Cardiology Guidelines for the management of patients with supraventricular tachycardia: What is new, and what has changed? Anatol J Cardiol 2019;22:282-6. [PMID: 31789617 DOI: 10.14744/AnatolJCardiol.2019.93507] [Reference Citation Analysis]
85 Favaloro EJ, Gilmore G, Arunachalam S, Mohammed S, Baker R. Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. Thrombosis Research 2019;180:10-9. [DOI: 10.1016/j.thromres.2019.05.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
86 Kezerle L, Tsadok MA, Berliner Senderey A, Hoshen M, Leventer‐roberts M, Reges O, Leibowitz M, Haim M. Use of oral anticoagulation therapy in the first 3 months after the diagnosis of atrial fibrillation in Israel: A population‐based study. J Cardiovasc Electrophysiol 2020;31:1356-63. [DOI: 10.1111/jce.14452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Zathar Z, Karunatilleke A, Fawzy AM, Lip GYH. Atrial Fibrillation in Older People: Concepts and Controversies. Front Med (Lausanne) 2019;6:175. [PMID: 31440508 DOI: 10.3389/fmed.2019.00175] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
88 Magnusson P, V. Pergolizzi Jr J, K. Wolf R, Lamberts M, Ann Lequang J. Anticoagulation in Atrial Fibrillation Patients. In: Cismaru G, Andrew Chan K, editors. Epidemiology and Treatment of Atrial Fibrillation. IntechOpen; 2020. [DOI: 10.5772/intechopen.88965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Kotalczyk A, Mazurek M, Kalarus Z, Potpara TS, Lip GYH. Stroke prevention strategies in high-risk patients with atrial fibrillation. Nat Rev Cardiol 2021;18:276-90. [PMID: 33110242 DOI: 10.1038/s41569-020-00459-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
90 Sun S, Su B, Lin J, Zhao C, Ma C. A nomogram to predict left atrial appendage thrombus and spontaneous echo contrast in non-valvular atrial fibrillation patients. BMC Cardiovasc Disord 2022;22:311. [PMID: 35820838 DOI: 10.1186/s12872-022-02737-z] [Reference Citation Analysis]
91 Albabtain MA, Alharthi MM, Dagriri K, Arafat AA, Ayrout E, Alhebaishi Y, AlFagih A. Assessment of the quality of anticoagulation management with warfarin in a tertiary care center. Saudi Med J 2020;41:1245-51. [PMID: 33130846 DOI: 10.15537/smj.2020.11.25456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
92 Patil T, Lebrecht M. A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. Thromb Res 2020;192:124-30. [PMID: 32473496 DOI: 10.1016/j.thromres.2020.04.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
93 Geller AI, Shehab N, Lovegrove MC, Rose KO, Weidle NJ, Goring SK, Budnitz DS. Emergency Visits for Oral Anticoagulant Bleeding. J Gen Intern Med 2020;35:371-3. [PMID: 31664597 DOI: 10.1007/s11606-019-05391-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
94 Dizon K, Ng PCK, Battistella M. A retrospective study of antithrombotic therapy use in an outpatient haemodialysis unit. J Clin Pharm Ther 2021. [PMID: 34129239 DOI: 10.1111/jcpt.13467] [Reference Citation Analysis]
95 Methavigul K. Revised HAS‐BLED score for bleeding prediction in atrial fibrillation patients with oral anticoagulants. Journal of Arrhythmia. [DOI: 10.1002/joa3.12709] [Reference Citation Analysis]
96 Vigué B, Samama C, Charles P, Ritzenthaler T. Prise en charge hémostatique des hémorragies cérébrales sous anticoagulants oraux. Méd Intensive Réa 2019;28:363-70. [DOI: 10.3166/rea-2019-0113] [Reference Citation Analysis]
97 Zhan S, Liu F, Xia P, Tang M, Shu M, Zhang Z, Wu X; Cochrane Heart Group. Long-term antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease. Cochrane Database of Systematic Reviews 2021;2021. [DOI: 10.1002/14651858.cd014819] [Reference Citation Analysis]
98 Nielsen JC, Lin YJ, de Oliveira Figueiredo MJ, Sepehri Shamloo A, Alfie A, Boveda S, Dagres N, Di Toro D, Eckhardt LL, Ellenbogen K, Hardy C, Ikeda T, Jaswal A, Kaufman E, Krahn A, Kusano K, Kutyifa V, Lim HS, Lip GYH, Nava-Townsend S, Pak HN, Diez GR, Sauer W, Saxena A, Svendsen JH, Vanegas D, Vaseghi M, Wilde A, Bunch TJ, Buxton AE, Calvimontes G, Chao TF, Eckardt L, Estner H, Gillis AM, Isa R, Kautzner J, Maury P, Moss JD, Nam GB, Olshansky B, Pava Molano LF, Pimentel M, Prabhu M, Tzou WS, Sommer P, Swampillai J, Vidal A, Deneke T, Hindricks G, Leclercq C; ESC Scientific Document Group. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Heart Rhythm 2020;17:e269-316. [PMID: 32553607 DOI: 10.1016/j.hrthm.2020.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
99 Sanchez JM, Jolly SE, Dewland TA, Tseng ZH, Nah G, Vittinghoff E, Marcus GM. Incident Strokes Among American Indian Individuals With Atrial Fibrillation. J Am Heart Assoc 2021;10:e019581. [PMID: 33653124 DOI: 10.1161/JAHA.120.019581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Cave BE, Shah SP. Turning Up to Eleven: Factor XI Inhibitors as Novel Agents to Maximize Safety and Maintain Efficacy in Thromboembolic Disease. Curr Probl Cardiol 2021;46:100696. [PMID: 32994051 DOI: 10.1016/j.cpcardiol.2020.100696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Margaglione M, Antonucci E, D'Andrea G, Migliaccio L, Ageno W, Bucherini E, Cosmi B, Falanga A, Martini G, Mastroiacovo D, Paparo C, Poli D, Testa S, Palareti G. Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study. Blood Transfus 2020;18:486-95. [PMID: 32955425 DOI: 10.2450/2020.0091-20] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
102 Ahn J, Shin SY, Shim J, Kim YH, Han SJ, Choi EK, Oh S, Shin JY, Choe JC, Park JS, Lee HW, Oh JH, Choi JH, Lee HC, Cha KS, Hong TJ, Lip GYH, Lim HE. Association between epicardial adipose tissue and embolic stroke after catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2019;30:2209-16. [PMID: 31502330 DOI: 10.1111/jce.14154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
103 Tinkham TT, Vazquez SR, Jones AE, Witt DM. Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. J Thromb Thrombolysis 2020;49:492-6. [PMID: 31776847 DOI: 10.1007/s11239-019-01999-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
104 Han S, Han S, Jang SW, Lee MY, On YK, Bang OY, Lee JM, Park YJ, Shin JS, Kang S, Suh HS, Kim YH. Treatment Pattern of Antithrombotic Therapy over Time after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation in Real-World Practice in Korea. Healthcare (Basel) 2021;9:1185. [PMID: 34574959 DOI: 10.3390/healthcare9091185] [Reference Citation Analysis]
105 Pasciolla S, Wojcik K, Kavi T, Green D, Shaikh H, Jankowitz B, Igneri LA. Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage. J Thromb Thrombolysis 2021. [PMID: 34837144 DOI: 10.1007/s11239-021-02613-1] [Reference Citation Analysis]
106 Kumar S, Lim E, Covic A, Verhamme P, Gale CP, Camm AJ, Goldsmith D. Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol 2019;74:2204-15. [PMID: 31648714 DOI: 10.1016/j.jacc.2019.08.1031] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
107 Gupta R, Desai R, Gupta N. Reply to "Non-vitamin K antagonist oral anticoagulants for atrial fibrillation in obese patients". Am J Cardiol 2020;130:167-8. [PMID: 32641216 DOI: 10.1016/j.amjcard.2020.06.008] [Reference Citation Analysis]
108 Kozieł M, Potpara TS, Lip GYH. Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting. Res Pract Thromb Haemost 2020;4:357-65. [PMID: 32211570 DOI: 10.1002/rth2.12319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Ording AG, Søgaard M, Skjøth F, Grove EL, Lip GYH, Larsen TB, Nielsen PB. Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. Cancer Med 2021;10:4405-14. [PMID: 34114733 DOI: 10.1002/cam4.4012] [Reference Citation Analysis]
110 Kumbhani DJ, Cannon CP, Beavers CJ, Bhatt DL, Cuker A, Gluckman TJ, Marine JE, Mehran R, Messe SR, Patel NS, Peterson BE, Rosenfield K, Spinler SA, Thourani VH. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology 2021;77:629-58. [DOI: 10.1016/j.jacc.2020.09.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
111 Li Y, Lip GY. Stroke prevention in atrial fibrillation: State of the art. International Journal of Cardiology 2019;287:201-9. [DOI: 10.1016/j.ijcard.2018.09.057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
112 Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, Guo Y, Sriratanasathavorn C, Oh S, Okumura K, Lip GYH. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thromb Haemost 2021. [PMID: 34773920 DOI: 10.1055/s-0041-1739411] [Reference Citation Analysis]
113 Rali P, Gangemi A, Moores A, Mohrien K, Moores L. Direct-Acting Oral Anticoagulants in Critically Ill Patients. Chest 2019;156:604-18. [PMID: 31251908 DOI: 10.1016/j.chest.2019.05.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Galante A, De Gottardi A. Portal vein thrombosis: an overview of current treatment options. Acta Gastroenterol Belg 2021;84:327-32. [PMID: 34217184 DOI: 10.51821/84.2.327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology 2022:S0016-5085(21)04083-X. [PMID: 35183361 DOI: 10.1053/j.gastro.2021.12.247] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
116 Mavrakanas TA, Charytan DM, Winkelmayer WC. Direct oral anticoagulants in chronic kidney disease: an update. Curr Opin Nephrol Hypertens 2020;29:489-96. [PMID: 32740218 DOI: 10.1097/MNH.0000000000000634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 De Caterina R, Agnelli G, Laeis P, Unverdorben M, Rauer H, Wang CC, Nakamura M, Chiu KM, Reimitz PE, Koretsune Y, Chen C, Thee U, Kaburagi J, Kim YH, Choi WI, Yamashita T, Cohen A, Kirchhof P. The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design. Clin Cardiol 2019;42:1147-54. [PMID: 31650560 DOI: 10.1002/clc.23279] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
118 Lewin AR, Collins PE, Sylvester KW, Rimsans J, Fanikos J, Goldhaber SZ, Connors JM. Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. Crit Pathw Cardiol 2020;19:178-86. [PMID: 33186279 DOI: 10.1097/HPC.0000000000000221] [Reference Citation Analysis]
119 Huang ZC, Li CQ, Liu XY, Cao ZC, Jia HY, Dong Y, Liu TL, Sun JJ. Efficacy and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Liver Disease: a Meta-Analysis and Systematic Review. Cardiovasc Drugs Ther 2021;35:1205-15. [PMID: 32880804 DOI: 10.1007/s10557-020-07065-y] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 See L, Lee H, Chao T, Li P, Liu J, Wu L, Chang S, Yeh Y, Kuo C, Chan Y, Lip GYH. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis. Cardiovasc Drugs Ther 2021;35:975-86. [DOI: 10.1007/s10557-020-07108-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
121 Potpara TS, Ferro C, Lip GYH, Dan GA, Lenarczyk R, Mallamaci F, Ortiz A, Sarafidis P, Ekart R, Dagres N. Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. EP Europace 2020;22:496-505. [DOI: 10.1093/europace/euz358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
122 Lee SR, Rhee TM, Kang DY, Choi EK, Oh S, Lip GYH. Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation. Am J Cardiol 2019;124:879-85. [PMID: 31311662 DOI: 10.1016/j.amjcard.2019.05.072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
123 Ng DL, Gan GG, Chai CS, Chee KH, Tan KL, Tan SB, Bee PC. Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study. Patient Prefer Adherence 2019;13:1363-73. [PMID: 31616136 DOI: 10.2147/PPA.S204246] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
124 Billings JD, Khan AD, McVicker JH, Schroeppel TJ. Newer and Better? Comparing Direct Oral Anticoagulants to Warfarin in Patients With Traumatic Intracranial Hemorrhage. Am Surg 2020;86:1062-6. [PMID: 33049165 DOI: 10.1177/0003134820942204] [Reference Citation Analysis]
125 Shen NN, Zhang C, Hang Y, Li Z, Kong LC, Wang N, Wang JL, Gu ZC. Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis. Front Pharmacol 2021;12:581293. [PMID: 34122056 DOI: 10.3389/fphar.2021.581293] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Riva N, Xuereb CB, Ageno W, Makris M, Gatt A. Patients' satisfaction associated with portable coagulometers for warfarin monitoring: a cross-sectional study. Blood Transfus 2020;18:386-95. [PMID: 32530403 DOI: 10.2450/2020.0005-20] [Reference Citation Analysis]
127 Winijkul A, Kaewkumdee P, Yindeengam A, Krittayaphong R. Characteristics and antithrombotic treatment patterns of patients with concomitant coronary artery disease and atrial fibrillation from Thailand's COOL-AF registry. BMC Cardiovasc Disord 2021;21:117. [PMID: 33653277 DOI: 10.1186/s12872-021-01928-4] [Reference Citation Analysis]
128 Ding Z, Zhang C, Qian YY, Wang N, Gu ZC, Xu H, Zheng YL. Rationale and design of a prospective, multicenter, cross-sectional study of appropriateness evaluation of the prescription of non-vitamin K antagonist oral anticoagulants for Chinese atrial fibrillation patients (Chi-NOACs-AF trial). Ann Transl Med 2021;9:580. [PMID: 33987278 DOI: 10.21037/atm-20-6893] [Reference Citation Analysis]
129 Mongkhon P, Alwafi H, Fanning L, Lau WCY, Wei L, Kongkaew C, Wong ICK. Patterns and factors influencing oral anticoagulant prescription in people with atrial fibrillation and dementia: Results from UK primary care. Br J Clin Pharmacol 2021;87:1056-68. [PMID: 32643166 DOI: 10.1111/bcp.14464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Gulilat M, Jandoc R, Jeyakumar N, Mcarthur E, Garg AX, Kim RB, Tirona RG, Schwarz UI. Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights. CJC Open 2022;4:56-64. [DOI: 10.1016/j.cjco.2021.09.002] [Reference Citation Analysis]
131 Savinova AV, Petrova MM, Shnayder NA, Bochanova EN, Nasyrova RF. Pharmacokinetics and Pharmacogenetics of Apixaban. Racionalʹnaâ farmakoterapiâ v kardiologii 2020;16:852-60. [DOI: 10.20996/1819-6446-2020-10-17] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
132 Osteraas ND, Sagalovich M, Glover JJ, Dafer RM. Timing of Anticoagulation after Stroke in Patients with Non-Valvular Atrial Fibrillation Assessment of Provider Practices. J Stroke Cerebrovasc Dis 2021;30:106014. [PMID: 34364012 DOI: 10.1016/j.jstrokecerebrovasdis.2021.106014] [Reference Citation Analysis]
133 Peled H, Dau NQ. Prothrombin Complex Concentrate or Coagulation Factor Xa (Recombinant), Inactivated-zhzo. Chest 2019;155:1308. [PMID: 31174650 DOI: 10.1016/j.chest.2019.02.335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
134 Königsbrügge O, Meisel H, Beyer A, Schmaldienst S, Klauser-Braun R, Lorenz M, Auinger M, Kletzmayr J, Hecking M, Winkelmayer WC, Lang I, Pabinger I, Säemann M, Ay C. Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study. J Thromb Haemost 2021;19:2984-96. [PMID: 34418291 DOI: 10.1111/jth.15508] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Gray JA, Lugo RA, Patel VN, Pohland CJ, Stewart DW. First evidence for a pharmacist-led anticoagulant clinic in a medicare part A long term care environment. J Thromb Thrombolysis 2019;48:690-3. [PMID: 31559511 DOI: 10.1007/s11239-019-01963-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
136 Calderon JM, Martinez F, Fernandez A, Sauri I, Diaz J, Uso R, Trillo JL, Redon J, Forner MJ. Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status. Sci Rep 2022;12:6123. [PMID: 35414001 DOI: 10.1038/s41598-022-10164-5] [Reference Citation Analysis]
137 Kuo L, Chan YH, Liao JN, Chen SA, Chao TF. Stroke and Bleeding Risk Assessment in Atrial Fibrillation: Where Are We Now? Korean Circ J 2021;51:668-80. [PMID: 34227269 DOI: 10.4070/kcj.2021.0170] [Reference Citation Analysis]
138 Attia ZI, Noseworthy PA, Lopez-jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, Carter RE, Yao X, Rabinstein AA, Erickson BJ, Kapa S, Friedman PA. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. The Lancet 2019;394:861-7. [DOI: 10.1016/s0140-6736(19)31721-0] [Cited by in Crossref: 245] [Cited by in F6Publishing: 88] [Article Influence: 81.7] [Reference Citation Analysis]
139 Zulkifly H, Lip GYH, Lane DA, Wang K. Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention. International Journal of Clinical Practice 2022;2022:1-8. [DOI: 10.1155/2022/5951262] [Reference Citation Analysis]
140 Hitchcock ZR, Smith SD, Le LT, Lees LR, Brandt MD. A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings. J Pharm Pract 2021;:8971900211026839. [PMID: 34231410 DOI: 10.1177/08971900211026839] [Reference Citation Analysis]
141 Chang T, Lip GY, Chen S, Chao T. Importance of Risk Reassessment in Patients With Atrial Fibrillation in Guidelines: Assessing Risk as a Dynamic Process. Canadian Journal of Cardiology 2019;35:611-8. [DOI: 10.1016/j.cjca.2019.01.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
142 Nielsen PB, Buchan I, Lip GYH. Etiological Research Using Observational Data, and Net Clinical Benefit. Simplicity and Practicality Matter. Am J Med 2019;132:671-2. [PMID: 30849380 DOI: 10.1016/j.amjmed.2019.01.038] [Reference Citation Analysis]
143 Boriani G, Huisman MV, Teutsch C, Marler S, França LR, Lu S, Lip GY. Influence of BMI and geographical region on prescription of oral anticoagulants in newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program. European Journal of Internal Medicine 2020;80:35-44. [DOI: 10.1016/j.ejim.2020.04.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
144 Marcolini E, Stretz C, DeWitt KM. Intracranial Hemorrhage and Intracranial Hypertension. Emerg Med Clin North Am 2019;37:529-44. [PMID: 31262419 DOI: 10.1016/j.emc.2019.04.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
145 Gumprecht J, Domek M, Lip GYH. A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention. Expert Opin Drug Saf 2019;18:1119-25. [PMID: 31580164 DOI: 10.1080/14740338.2019.1676723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
146 Kozieł M, Simovic S, Pavlovic N, Nedeljkovic M, Paparisto V, Music L, Goshev E, Dan AR, Manola S, Kusljugic Z, Trendafilova E, Dobrev D, Dan GA, Lip GYH, Potpara TS; BALKAN-AF investigators. Management of patients with newly-diagnosed atrial fibrillation: Insights from the BALKAN-AF survey. Int J Cardiol Heart Vasc 2020;26:100461. [PMID: 32140551 DOI: 10.1016/j.ijcha.2019.100461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Guo Y, Guo J, Shi X, Yao Y, Sun Y, Xia Y, Yu B, Liu T, Chen Y, Lip GYH; mAF-App II Trial investigators. Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort. Eur J Intern Med 2020;82:105-11. [PMID: 33067121 DOI: 10.1016/j.ejim.2020.09.024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 14.5] [Reference Citation Analysis]
148 Tran NT, Lin CH, Do NN, Muradian IK, Lu QD, Henderson SO. The Impact of Implementing an Advance Practice Pharmacist-Led Anticoagulation Clinic Within a Correctional Facility. J Pharm Pract 2021;34:631-4. [PMID: 31818177 DOI: 10.1177/0897190019892120] [Reference Citation Analysis]
149 Ding WY, Gupta D, Lip GYH. Physician Estimation of Thrombotic and Bleeding Risks in Atrial Fibrillation: Let's Talk About Sex. Can J Cardiol 2019;35:145-6. [PMID: 30760418 DOI: 10.1016/j.cjca.2018.12.011] [Reference Citation Analysis]
150 Patil T, Murphy K, Woodard L, Lebrecht M. Proton Pump Inhibitor Utilization in Veteran Patients on Combined Antithrombotic Therapy and Validation of Simplified Bleeding Risk Score. Pharmacotherapy 2020;40:1219-27. [PMID: 33073362 DOI: 10.1002/phar.2477] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Vitolo M, Javed S, Capodanno D, Rubboli A, Boriani G, Lip GYH. Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. Expert Review of Cardiovascular Therapy 2020;18:587-600. [DOI: 10.1080/14779072.2020.1808463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Schoen RR, Nagy MW, Porter AL, Margolis AR. Patient Satisfaction With Extended International Normalized Ratio Follow-up Intervals in a Veteran Population. Ann Pharmacother 2020;54:442-9. [PMID: 31752504 DOI: 10.1177/1060028019889414] [Reference Citation Analysis]
153 Kneihsl M, Gattringer T, Bisping E, Scherr D, Raggam R, Mangge H, Enzinger C, Fandler-Höfler S, Eppinger S, Hermetter C, Bucnik B, Poltrum B, Niederkorn K, Fazekas F. Blood Biomarkers of Heart Failure and Hypercoagulation to Identify Atrial Fibrillation-Related Stroke. Stroke 2019;50:2223-6. [PMID: 31216968 DOI: 10.1161/STROKEAHA.119.025339] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
154 Xian Y, Xu H, O'Brien EC, Shah S, Thomas L, Pencina MJ, Fonarow GC, Olson DM, Schwamm LH, Bhatt DL, Smith EE, Hannah D, Maisch L, Lytle BL, Peterson ED, Hernandez AF. Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. JAMA Neurol 2019;76:1192-202. [PMID: 31329212 DOI: 10.1001/jamaneurol.2019.2099] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 13.0] [Reference Citation Analysis]
155 Ammar AA, Ammar MA, Owusu KA, Brown SC, Kaddouh F, Elsamadicy AA, Acosta JN, Falcone GJ. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage. Neurocrit Care 2021;35:255-61. [PMID: 33403588 DOI: 10.1007/s12028-020-01161-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
156 Best JG, Bell R, Haque M, Chandratheva A, Werring DJ. Atrial fibrillation and stroke: a practical guide. Pract Neurol 2019;19:208-24. [PMID: 30826740 DOI: 10.1136/practneurol-2018-002089] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
157 Shaikh F, Wynne R, Castelino RL, Inglis SC, Ferguson C. Effectiveness of Direct Oral Anticoagulants in Obese Adults With Atrial Fibrillation: A Systematic Review of Systematic Reviews and Meta-Analysis. Front Cardiovasc Med 2021;8:732828. [PMID: 34692784 DOI: 10.3389/fcvm.2021.732828] [Reference Citation Analysis]
158 Beyene K, Chan AHY, Näslund P, Harrison J. Patient-related factors associated with oral anticoagulation control: a population-based cohort study. Int J Pharm Pract 2021:riab041. [PMID: 34302345 DOI: 10.1093/ijpp/riab041] [Reference Citation Analysis]
159 Lee SR, Lee HJ, Choi EK, Han KD, Jung JH, Cha MJ, Oh S, Lip GYH. Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease. J Am Coll Cardiol 2019;73:3295-308. [PMID: 31248551 DOI: 10.1016/j.jacc.2019.04.052] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 22.0] [Reference Citation Analysis]
160 Wilke TJ, Fremming BA, Brown BA, Markin NW, Kassel CA. 2020 Clinical Update in Liver Transplantation. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00100-2. [PMID: 33653578 DOI: 10.1053/j.jvca.2021.02.005] [Reference Citation Analysis]
161 Nielsen JC, Lin YJ, de Oliveira Figueiredo MJ, Sepehri Shamloo A, Alfie A, Boveda S, Dagres N, Di Toro D, Eckhardt LL, Ellenbogen K, Hardy C, Ikeda T, Jaswal A, Kaufman E, Krahn A, Kusano K, Kutyifa V, S Lim H, Lip GYH, Nava-Townsend S, Pak HN, Rodríguez Diez G, Sauer W, Saxena A, Svendsen JH, Vanegas D, Vaseghi M, Wilde A, Bunch TJ, Buxton AE, Calvimontes G, Chao TF, Eckardt L, Estner H, Gillis AM, Isa R, Kautzner J, Maury P, Moss JD, Nam GB, Olshansky B, Molano LFP, Pimentel M, Prabhu M, Tzou WS, Sommer P, Swampillai J, Vidal A, Deneke T, Hindricks G, Leclercq C. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. J Arrhythm 2020;36:553-607. [PMID: 32782627 DOI: 10.1002/joa3.12338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
162 Karamchandani K, Khanna AK, Bose S, Fernando RJ, Walkey AJ. Atrial Fibrillation: Current Evidence and Management Strategies During the Perioperative Period. Anesthesia & Analgesia 2020;130:2-13. [DOI: 10.1213/ane.0000000000004474] [Cited by in Crossref: 8] [Article Influence: 4.0] [Reference Citation Analysis]
163 Kotalczyk A, Ding WY, Gupta D, Wright DJ, Lip GYH. Clinical outcomes following rhythm control for atrial fibrillation: is early better? Expert Rev Cardiovasc Ther 2021;19:277-87. [PMID: 33715565 DOI: 10.1080/14779072.2021.1902307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Vanneman MW, Dalia AA. Positioning for Perioperative Success: Insights from the European Society of Cardiology Statement on Atrial Fibrillation and Acute Heart Failure. J Cardiothorac Vasc Anesth 2020;34:2871-5. [PMID: 32732097 DOI: 10.1053/j.jvca.2020.06.055] [Reference Citation Analysis]
165 Magnocavallo M, Bellasi A, Mariani MV, Fusaro M, Ravera M, Paoletti E, Di Iorio B, Barbera V, Della Rocca DG, Palumbo R, Severino P, Lavalle C, Di Lullo L. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. J Clin Med 2020;10:E83. [PMID: 33379379 DOI: 10.3390/jcm10010083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
166 Dzeshka MS, Lip GYH. Editorial commentary: Reversal agents in the era of non-vitamin k antagonists oral anticoagulants: Necessity or psychological crutch? Trends Cardiovasc Med 2020;30:91-2. [PMID: 31072696 DOI: 10.1016/j.tcm.2019.04.007] [Reference Citation Analysis]
167 Sun B, Wen YF, Culhane-Pera KA, Lo M, Xiong T, Lee K, Peng K, Thyagarajan B, Bishop JR, Zierhut H, Straka RJ. Differences in Predicted Warfarin Dosing Requirements Between Hmong and East Asians Using Genotype-Based Dosing Algorithms. Pharmacotherapy 2021;41:265-76. [PMID: 33202062 DOI: 10.1002/phar.2487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
168 Xiao X, Han H, Wu C, He Q, Ruan Y, Zhai Y, Gao Y, Zhao X, He J. Prevalence of Atrial Fibrillation in Hospital Encounters With End-Stage COPD on Home Oxygen. Chest 2019;155:918-27. [DOI: 10.1016/j.chest.2018.12.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
169 Vitolo M, Malavasi VL, Proietti M, Diemberger I, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lane DA, Lip GYH, Boriani G; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. Eur J Intern Med 2022:S0953-6205(22)00037-1. [PMID: 35177307 DOI: 10.1016/j.ejim.2022.01.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Zhao N, Liu Z, Xie Q, Wang Z, Sun Z, Xiang Q, Cui Y. A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation. Front Pharmacol 2022;13:814724. [DOI: 10.3389/fphar.2022.814724] [Reference Citation Analysis]
171 Benetou DR, Varlamos C, Mpahara A, Alexopoulos D. Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Am J Cardiovasc Drugs 2021;21:11-20. [PMID: 32170515 DOI: 10.1007/s40256-020-00403-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
172 Freedman B, Kamel H, Van Gelder IC, Schnabel RB. Atrial fibrillation: villain or bystander in vascular brain injury. Eur Heart J Suppl 2020;22:M51-9. [PMID: 33664640 DOI: 10.1093/eurheartj/suaa166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
173 Coates J, Bitton E, Hendje A, Delate T, Olson KL, Knowles C, Ly S, Fink KM, Clark NP. Clinical outcomes of dabigatran use in patients with non-valvular atrial fibrillation and weight >120 kg. Thromb Res 2021;208:176-80. [PMID: 34808409 DOI: 10.1016/j.thromres.2021.11.007] [Reference Citation Analysis]
174 Lee LC, Farwig P, Kirk L, Mitchell VD, Sabatino JA, Barnes KD. Impact of pharmacist intervention on anticoagulation management and risk for potential COVID-19 exposure during the COVID-19 pandemic. Thromb Res 2022;217:52-6. [PMID: 35868151 DOI: 10.1016/j.thromres.2022.07.004] [Reference Citation Analysis]
175 Wattanaruengchai P, Nathisuwan S, Rattanavipanon W, Chulavatnatol S, Kongwatcharapong J, Mitsuntisuk P, Chaiyasothi T, Kritsanapipat D, Phrommintikul A, Chaiyakunapruk N, Likittanasombat K, Lip GYH. Prescriber compliance to direct oral anticoagulant labels and impact on outcomes in Thailand. Br J Clin Pharmacol 2021;87:1390-400. [PMID: 32857417 DOI: 10.1111/bcp.14535] [Reference Citation Analysis]
176 Krittayaphong R, Kunjara-Na-Ayudhya R, Ngamjanyaporn P, Boonyaratavej S, Komoltri C, Yindeengam A, Sritara P, Lip GYH, For The Cool-Af Investigators. Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand. J Geriatr Cardiol 2020;17:612-20. [PMID: 33224180 DOI: 10.11909/j.issn.1671-5411.2020.10.004] [Reference Citation Analysis]
177 Owusu KA, Effendi MK, DeFilippo NA, Reardon DP, Ian Lee A. Andexanet Alfa: Considerations and Practical Applications. Crit Pathw Cardiol 2019;18:200-6. [PMID: 31725512 DOI: 10.1097/HPC.0000000000000190] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
178 Krittayaphong R, Aroonsiriwattana S, Ngamjanyaporn P, Patmuk T, Kaewkumdee P; COOL-AF Investigators. Outcomes of patients with atrial fibrillation with and without diabetes: A propensity score matching of the COOL-AF registry. Int J Clin Pract 2021;:e14671. [PMID: 34324768 DOI: 10.1111/ijcp.14671] [Reference Citation Analysis]
179 Boriani G, Vitolo M, Lane DA, Potpara TS, Lip GY. Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. Eur J Intern Med 2021;86:1-11. [PMID: 33518403 DOI: 10.1016/j.ejim.2021.01.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
180 Zerah L, Bun RS, Guillo S, Collet JP, Bonnet-Zamponi D, Tubach F. A prescription support-tool for chronic management of oral antithrombotic combinations in adults based on a systematic review of international guidelines. PLoS One 2019;14:e0211695. [PMID: 30763325 DOI: 10.1371/journal.pone.0211695] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
181 Malavasi VL, Zoccali C, Brandi MC, Micali G, Vitolo M, Imberti JF, Mussi C, Schnabel RB, Freedman B, Boriani G. Cognitive impairment in patients with atrial fibrillation: Implications for outcome in a cohort study. Int J Cardiol 2021;323:83-9. [PMID: 32800908 DOI: 10.1016/j.ijcard.2020.08.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
182 Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, López-Fernández T, Gale CP, Maduro JH, Moslehi J, Omland T, Plana Gomez JC, Scott J, Suter TM, Minotti G. The cancer patient and cardiology. Eur J Heart Fail 2020;22:2290-309. [PMID: 32809231 DOI: 10.1002/ejhf.1985] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
183 Bang OY, On YK, Lee MY, Jang SW, Han S, Han S, Won MM, Park YJ, Lee JM, Choi HY, Kang S, Suh HS, Kim YH. The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis. PLoS One 2020;15:e0242922. [PMID: 33253294 DOI: 10.1371/journal.pone.0242922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
184 Harenberg J, Bauersachs R, Ageno W. Does Chronic Treatment with Oral Anticoagulants Ameliorate the Clinical Course of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Coronavirus Disease 2019 (COVID-19)? Semin Thromb Hemost 2021;47:338-40. [PMID: 32882715 DOI: 10.1055/s-0040-1715091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
185 Pastori D, Baratta F, Di Rocco A, Farcomeni A, Del Ben M, Angelico F, Violi F, Pignatelli P, Lip GYH. Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. Pharmacol Res 2021;165:105418. [PMID: 33450384 DOI: 10.1016/j.phrs.2021.105418] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
186 Domek M, Gumprecht J, Lip GYH, Shantsila A. Malignant hypertension: does this still exist? J Hum Hypertens 2020;34:1-4. [DOI: 10.1038/s41371-019-0267-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
187 Chan NC, Eikelboom JW. How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. Blood 2019;133:2269-78. [PMID: 30926593 DOI: 10.1182/blood-2019-01-846048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
188 Migliore F, Providencia R, Farkowski MM, Dan GA, Daniel S, Potpara TS, Jubele K, Chun JKR, de Asmundis C, Zorzi A, Boveda S. Antithrombotic treatment management in low stroke risk patients undergoing cardioversion of atrial fibrillation <48 h duration: results of an EHRA survey. Europace 2021:euab106. [PMID: 33990842 DOI: 10.1093/europace/euab106] [Reference Citation Analysis]
189 Puttasung N, Davey AK, Badrick T, Anoopkumar-Dukie S, Bernaitis N. Time to Stable Therapeutic Range on Initiation of Warfarin as an Indicator of Control. J Stroke Cerebrovasc Dis 2021;30:105620. [PMID: 33493875 DOI: 10.1016/j.jstrokecerebrovasdis.2021.105620] [Reference Citation Analysis]
190 Lee SR, Choi EK, Jung JH, Han KD, Oh S, Lip GYH. Smoking Cessation after Diagnosis of New-Onset Atrial Fibrillation and the Risk of Stroke and Death. J Clin Med 2021;10:2238. [PMID: 34064089 DOI: 10.3390/jcm10112238] [Reference Citation Analysis]
191 Zhang J, Thabane L, Li Z, Li G. Editorial: Antithrombotic Prophylaxis in Patients With Atrial Fibrillation for Stroke Prevention: Evidence From Randomized Clinical Trials, Observational Studies, Methodological Modeling, and More. Front Med (Lausanne) 2021;8:658303. [PMID: 33681268 DOI: 10.3389/fmed.2021.658303] [Reference Citation Analysis]
192 Sadowski CA, Bharadia M, Bowles SK, Isenor JE, Patel T. Review of the top 5 geriatrics studies of 2018-2019. Can Pharm J (Ott) 2021;154:256-61. [PMID: 34345318 DOI: 10.1177/17151635211018725] [Reference Citation Analysis]
193 Chao TF, Chiang CE, Liao JN, Chen TJ, Lip GYH, Chen SA. Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. Chest 2020;157:1266-77. [PMID: 31809694 DOI: 10.1016/j.chest.2019.11.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
194 Guo Y, Lip GY. Mobile Health for Cardiovascular Disease: The New Frontier for AF Management: Observations from the Huawei Heart Study and mAFA-II Randomised Trial. Arrhythm Electrophysiol Rev 2020;9:5-7. [PMID: 32637113 DOI: 10.15420/aer.2020.12] [Reference Citation Analysis]
195 Chen A, Stecker E, A Warden B. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. J Am Heart Assoc 2020;9:e017559. [PMID: 32538234 DOI: 10.1161/JAHA.120.017559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 13.5] [Reference Citation Analysis]
196 Ding WY, Lane DA, Gupta D, Huisman MV, Lip GYH; GLORIA‐AF Investigators. Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry. J Am Heart Assoc 2022;:e026410. [PMID: 35876418 DOI: 10.1161/JAHA.122.026410] [Reference Citation Analysis]
197 Proietti M, Vitolo M, Lip GYH. Integrated care and outcomes in patients with atrial fibrillation and comorbidities. Eur J Clin Invest 2021;51:e13498. [PMID: 33482011 DOI: 10.1111/eci.13498] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
198 Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, Chu PH. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol 2020;19:188. [PMID: 33158436 DOI: 10.1186/s12933-020-01162-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
199 Ding WY. Residual Stroke Risk in Atrial Fibrillation. Arrhythm Electrophysiol Rev 2021;10:147-53. [PMID: 34777818 DOI: 10.15420/aer.2021.34] [Reference Citation Analysis]
200 Gorog DA, Gue YX, Chao TF, Fauchier L, Ferreiro JL, Huber K, Konstantinidis SV, Lane DA, Marin F, Oldgren J, Potpara T, Roldan V, Rubboli A, Sibbing D, Tse HF, Vilahur G, Lip GYH. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost 2022. [PMID: 35793691 DOI: 10.1055/s-0042-1750385] [Reference Citation Analysis]
201 Santos IS, Lotufo PA, Brant L, Pinto Filho MM, Pereira ADC, Barreto SM, Ribeiro AL, Thomas GN, Lip GYH, Bensenor IM. Atrial Fibrillation Diagnosis using ECG Records and Self-Report in the Community: Cross-Sectional Analysis from ELSA-Brasil. Arq Bras Cardiol 2021;117:426-34. [PMID: 34550227 DOI: 10.36660/abc.20190873] [Reference Citation Analysis]
202 Mantovani A, Dauriz M, Sandri D, Bonapace S, Zoppini G, Tilg H, Byrne CD, Targher G. Association between non‐alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta‐analysis. Liver Int 2019;39:758-69. [DOI: 10.1111/liv.14044] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
203 Hafiz A, Abdulrahman I A, Sylvester KW, Connors JM, Rimsans J. Evaluation of anticoagulation re-initiation practices following reversal of factor Xa inhibitors with andexanet alfa or 4F-PCC in patients with major bleeding events. Thrombosis Update 2021;5:100076. [DOI: 10.1016/j.tru.2021.100076] [Reference Citation Analysis]
204 Riad FS, German K, Deitz S, Sahadevan J, Sundaram V, Waldo AL. Attitudes toward anticoagulation for postoperative atrial fibrillation: A nationwide survey of VA providers. Pacing Clin Electrophysiol 2020;43:1295-301. [DOI: 10.1111/pace.14095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
205 Wong BM, Perry JJ, Cheng W, Zheng B, Guo K, Taljaard M, Skanes AC, Stiell IG. Thromboembolic events following cardioversion of acute atrial fibrillation and flutter: a systematic review and meta-analysis. CJEM 2021;23:500-11. [PMID: 33715143 DOI: 10.1007/s43678-021-00103-0] [Reference Citation Analysis]
206 Kido K, Shimizu M, Shiga T, Hashiguchi M. Meta-analysis comparing inappropriately low dose versus standard dose of direct oral anticoagulants in patients with atrial fibrillation. J Am Pharm Assoc (2003) 2021:S1544-3191(21)00446-5. [PMID: 34815185 DOI: 10.1016/j.japh.2021.10.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 Gattellari M, Hayen A, Leung DYC, Zwar NA, Worthington JM. Supporting anticoagulant treatment decision making to optimise stroke prevention in complex patients with atrial fibrillation: a cluster randomised trial. BMC Fam Pract 2020;21:102. [PMID: 32513116 DOI: 10.1186/s12875-020-01175-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Kozieł M, Simovic S, Pavlovic N, Kocijancic A, Paparisto V, Music L, Trendafilova E, Dan AR, Kusljugic Z, Dan GA, Lip GYH, Potpara TS. Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. Ann Med 2021;53:17-25. [PMID: 32700579 DOI: 10.1080/07853890.2020.1799241] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
209 Siriez R, Yildiz H, Bouvy C, Haguet H, Maloteau V, Hardy M, Mullier F, Dogné J, Hainaut P, Douxfils J. The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12680] [Reference Citation Analysis]
210 Jones MJ, Eudaley ST, Moye RA, Hodge TA, Nesbit RM, Franks AS. Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment. J Thromb Thrombolysis 2020;50:330-6. [DOI: 10.1007/s11239-019-02028-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
211 Rech MA, Masic D, Hammond DA. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding. West J Emerg Med 2021;22:163-9. [PMID: 33856296 DOI: 10.5811/westjem.2020.11.47931] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Obeidat M, Burgess M, Lip GYH. Atrial Fibrillation in Heart Failure: Focus on Antithrombotic Management. Heart Fail Clin 2020;16:107-20. [PMID: 31735308 DOI: 10.1016/j.hfc.2019.08.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
213 Mitsuntisuk P, Nathisuwan S, Junpanichjaroen A, Wongcharoen W, Phrommintikul A, Wattanaruengchai P, Rattanavipanon W, Chulavatnatol S, Chaiyakunapruk N, Likittanasombat K, Lip GYH. Real-World Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in a Developing Country. Clin Pharmacol Ther 2021;109:1282-92. [PMID: 33113153 DOI: 10.1002/cpt.2090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
214 Xie Q, Li Y, Liu Z, Mu G, Zhang H, Zhou S, Wang Z, Wang Z, Jiang J, Li X, Xiang Q, Cui Y. SLC4A4, FRAS1, and SULT1A1 Genetic Variations Associated With Dabigatran Metabolism in a Healthy Chinese Population. Front Genet 2022;13:873031. [DOI: 10.3389/fgene.2022.873031] [Reference Citation Analysis]
215 Desai NR, Cornutt D. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists. Hosp Pract (1995) 2019;47:113-22. [PMID: 31317796 DOI: 10.1080/21548331.2019.1643728] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
216 van Miert JHA, Veeger NJGM, Meijer K. Is the time in therapeutic range on coumarins predicted by previous time in therapeutic range? Res Pract Thromb Haemost 2020;4:604-9. [PMID: 32548559 DOI: 10.1002/rth2.12328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
217 Santarelli A, Dietrich T, Sprague R, Ajao A, Ashurst J. Real world utilization of Andexanet Alfa at a community hospital. Am J Emerg Med 2021;45:627-8. [PMID: 33261947 DOI: 10.1016/j.ajem.2020.11.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
218 Favresse J, Hardy M, van Dievoet M, Sennesael A, Douxfils J, Samama C, Vornicu O, Dincq A, Lessire S, Mullier F. Andexanet alfa for the reversal of factor Xa inhibitors. Expert Opinion on Biological Therapy 2019;19:387-97. [DOI: 10.1080/14712598.2019.1599355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
219 Rowland B, Batty JA, Mehran R, Kunadian V. Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants after Percutaneous Coronary Intervention. In: Dangas GD, Di Mario C, Thiele H, Barlis P, Addo T, Claessen B, Hengstenberg C, Kipshidze N, editors. Interventional Cardiology. Wiley; 2022. pp. 453-64. [DOI: 10.1002/9781119697367.ch42] [Reference Citation Analysis]
220 Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet 2019;58:1265-79. [PMID: 31089975 DOI: 10.1007/s40262-019-00775-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 21.0] [Reference Citation Analysis]
221 Fernando SM, Mok G, Castellucci LA, Dowlatshahi D, Rochwerg B, McIsaac DI, Carrier M, Wells PS, Bagshaw SM, Fergusson DA, Tanuseputro P, Kyeremanteng K. Impact of Anticoagulation on Mortality and Resource Utilization Among Critically Ill Patients With Major Bleeding. Crit Care Med 2020;48:515-24. [PMID: 32205598 DOI: 10.1097/CCM.0000000000004206] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
222 Shapiro S, Benson G, Evans G, Harrison C, Mangles S, Makris M. Cardiovascular disease in hereditary haemophilia: The challenges of longevity. Br J Haematol 2022. [PMID: 35191019 DOI: 10.1111/bjh.18085] [Reference Citation Analysis]
223 Pastori D, Menichelli D, Violi F, Pignatelli P, Y H Lip G; ATHERO-AF study group. The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. Eur J Intern Med 2021;85:80-5. [PMID: 33358066 DOI: 10.1016/j.ejim.2020.12.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 Zhang X, Cai Q, Wang X, Liao K, Hu C, Chen H. Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE). J Thromb Thrombolysis 2021. [PMID: 33674983 DOI: 10.1007/s11239-021-02415-5] [Reference Citation Analysis]
225 Wijtvliet EPJP, Tieleman RG, van Gelder IC, Pluymaekers NAHA, Rienstra M, Folkeringa RJ, Bronzwaer P, Elvan A, Elders J, Tukkie R, Luermans JGLM, Van Asselt ADIT, Van Kuijk SMJ, Tijssen JG, Crijns HJGM; RACE 4 Investigators. Nurse-led vs. usual-care for atrial fibrillation. Eur Heart J 2020;41:634-41. [PMID: 31544925 DOI: 10.1093/eurheartj/ehz666] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
226 Prior A, Fiaschi P, Iaccarino C, Stefini R, Battaglini D, Balestrino A, Anania P, Prior E, Zona G. How do you manage ANTICOagulant therapy in neurosurgery? The ANTICO survey of the Italian Society of Neurosurgery (SINCH). BMC Neurol 2021;21:98. [PMID: 33658003 DOI: 10.1186/s12883-021-02126-7] [Reference Citation Analysis]
227 Liu J, Wang G, Qin L, Wu Y, Zou Y, Wang X, Wang Z, Wang Y, Zhang S, Zhang Y, Yin T. Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation. Cardiol Res Pract 2021;2021:9030005. [PMID: 34858664 DOI: 10.1155/2021/9030005] [Reference Citation Analysis]
228 Rawal A, Ardeshna D, Minhas S, Cave B, Ibeguogu U, Khouzam R. Current status of oral anticoagulant reversal strategies: a review. Ann Transl Med 2019;7:411. [PMID: 31660310 DOI: 10.21037/atm.2019.07.101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
229 Perreault S, Denus S, White‐guay B, Côté R, Schnitzer ME, Dubé M, Dorais M, Tardif J. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. Pharmacotherapy 2019;40:40-54. [DOI: 10.1002/phar.2350] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
230 Liu F, Zhang Y, Luo J, Zhou Y. Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis. Front Cardiovasc Med 2022;9:813419. [DOI: 10.3389/fcvm.2022.813419] [Reference Citation Analysis]
231 Deltour S, Pautas E. Anticoagulation decisions in elderly patients with stroke. Rev Neurol (Paris) 2020;176:692-700. [PMID: 32631675 DOI: 10.1016/j.neurol.2020.04.015] [Reference Citation Analysis]
232 Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C, Mundl H, Patel MR; PACIFIC-AF Investigators. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 2022:S0140-6736(22)00456-1. [PMID: 35385695 DOI: 10.1016/S0140-6736(22)00456-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
233 Chen A, Stecker E, A. Warden B. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. JAHA 2020;9:e017559. [DOI: 10.1161/jaha.120.017559] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
234 Wallenhorst C, Martinez C, Freedman B. Risk of Ischemic Stroke in Asymptomatic Atrial Fibrillation Incidentally Detected in Primary Care Compared with Other Clinical Presentations. Thromb Haemost 2021. [PMID: 34192776 DOI: 10.1055/a-1541-3885] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
235 Joung B, Lee JM, Lee KH, Kim TH, Choi EK, Lim WH, Kang KW, Shim J, Lim HE, Park J, Lee SR, Lee YS, Kim JB; KHRS Atrial Fibrillation Guideline Working Group. 2018 Korean Guideline of Atrial Fibrillation Management. Korean Circ J 2018;48:1033-80. [PMID: 30403013 DOI: 10.4070/kcj.2018.0339] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 15.0] [Reference Citation Analysis]
236 Kozieł M, Potpara TS, Lip GYH. Using Blood Biomarkers to Identify Atrial Fibrillation-Related Stroke. Stroke 2019;50:1956-7. [PMID: 31216960 DOI: 10.1161/STROKEAHA.119.026185] [Reference Citation Analysis]
237 Nielsen JC, Lin YJ, de Oliveira Figueiredo MJ, Sepehri Shamloo A, Alfie A, Boveda S, Dagres N, Di Toro D, Eckhardt LL, Ellenbogen K, Hardy C, Ikeda T, Jaswal A, Kaufman E, Krahn A, Kusano K, Kutyifa V, Lim HS, Lip GYH, Nava-Townsend S, Pak HN, Rodríguez Diez G, Sauer W, Saxena A, Svendsen JH, Vanegas D, Vaseghi M, Wilde A, Bunch TJ, Buxton AE, Calvimontes G, Chao TF, Eckardt L, Estner H, Gillis AM, Isa R, Kautzner J, Maury P, Moss JD, Nam GB, Olshansky B, Pava Molano LF, Pimentel M, Prabhu M, Tzou WS, Sommer P, Swampillai J, Vidal A, Deneke T, Hindricks G, Leclercq C; ESC Scientific Document Group. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Europace 2020;22:1147-8. [PMID: 32538434 DOI: 10.1093/europace/euaa065] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 22.0] [Reference Citation Analysis]
238 Hanni C, Petrovitch E, Ali M, Gibson W, Giuliano C, Holzhausen J, Makowski C, Pallisco A, Patel N, Sutter D, To L, Yost R. Outcomes associated with apixaban vs warfarin in patients with renal dysfunction. Blood Adv 2020;4:2366-71. [PMID: 32463871 DOI: 10.1182/bloodadvances.2019000972] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
239 Overvad TF, Skjøth F, Albertsen IE, Larsen TB, Søgaard M, Lip GYH. Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation? Am J Med 2021;134:67-75.e5. [PMID: 32634387 DOI: 10.1016/j.amjmed.2020.05.042] [Reference Citation Analysis]
240 Capiau A, Mehuys E, Dhondt E, De Backer T, Boussery K. Physicians' and pharmacists' views and experiences regarding use of direct oral anticoagulants in clinical practice. Br J Clin Pharmacol 2021. [PMID: 34625983 DOI: 10.1111/bcp.15106] [Reference Citation Analysis]
241 Nagaraj TA, Snider MJ, Davidson E, Weiss R, Li J, Afzal M. Risk Versus Benefit of Combined Aspirin and Warfarin Therapy in Patients With Atrial Fibrillation. J Pharm Pract 2021;34:766-73. [PMID: 32292101 DOI: 10.1177/0897190020916638] [Reference Citation Analysis]
242 Park J, Jung JH, Choi EK, Lee SW, Kwon S, Lee SR, Kang J, Han KD, Park KW, Oh S, Lip GYH. Longitudinal Patterns in Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention in the Non-Vitamin K Oral Anticoagulant Era: A Nationwide Population-Based Study. J Clin Med 2021;10:1505. [PMID: 33916604 DOI: 10.3390/jcm10071505] [Reference Citation Analysis]
243 Liu C, Du X, Jiang C, He L, Chang SS, Guo XY, Yu RH, Long DY, Bai R, Liu N, Sang CH, Jiang CX, Dong JZ, Lip GYH, Ma CS. Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry. Med Sci Monit 2019;25:2649-57. [PMID: 30971681 DOI: 10.12659/MSM.915875] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
244 Carballo Álvarez F, Albillos Martínez A, Llamas Silero P, Orive Calzada A, Redondo-cerezo E, Rodríguez de Santiago E, Crespo García J. Consensus document of the Sociedad Española de Patología Digestiva on massive nonvariceal gastrointestinal bleeding and direct-acting oral anticoagulants. Rev Esp Enferm Dig 2022. [DOI: 10.17235/reed.2022.8920/2022] [Reference Citation Analysis]
245 Ulivi L, Squitieri M, Cohen H, Cowley P, Werring DJ. Cerebral venous thrombosis: a practical guide. Pract Neurol 2020;20:356-67. [PMID: 32958591 DOI: 10.1136/practneurol-2019-002415] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
246 Proietti M, Romiti GF, Vitolo M, Potpara TS, Boriani G, Lip GYH. Comparison of HAS-BLED and ORBIT Bleeding Risk Scores in AF Patients treated with NOACs: A Report from the ESC-EHRA EORP-AF General Long-Term Registry. Eur Heart J Qual Care Clin Outcomes 2021:qcab069. [PMID: 34555148 DOI: 10.1093/ehjqcco/qcab069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
247 Bernstein MR, John L, Sciortino S, Arambages E, Auletta D, Spyropoulos AC. Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project. J Thromb Thrombolysis 2020;49:316-20. [PMID: 31898275 DOI: 10.1007/s11239-019-02031-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
248 Pham Nguyen TP, Chen Y, Thibault D, Leonard CE, Hennessy S, Willis A. Impact of Hospitalization and Medication Switching on Post-discharge Adherence to Oral Anticoagulants in Patients With Atrial Fibrillation. Pharmacotherapy 2020;40:1022-35. [PMID: 32869324 DOI: 10.1002/phar.2457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
249 Arlett P, Kurz X, Soltys K, Blum MD. International Collaboration in Real-World Evidence Generation for Direct Acting Oral Anti-Coagulants. Clin Pharmacol Ther 2021;109:299-301. [PMID: 32857416 DOI: 10.1002/cpt.1999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
250 Díaz-guzmán J, Freixa-pamias R, García-alegría J, Pérez Cabeza A, Roldán-rabadán I, Antolin-fontes B, Rebollo P, Llorac A, Genís-gironés M, Escobar-cervantes C. Epidemiología del ictus cardioembólico y su asociación con la penetración de los ACOD en España: primer estudio poblacional 2005-2018. Revista Española de Cardiología 2021. [DOI: 10.1016/j.recesp.2021.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
251 Frontera JA, Bhatt P, Lalchan R, Yaghi S, Ahuja T, Papadopoulos J, Joset D. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. J Thromb Thrombolysis 2020;49:121-31. [DOI: 10.1007/s11239-019-01973-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 7.7] [Reference Citation Analysis]
252 Rivera-caravaca JM, Marín F, Vilchez JA, Gálvez J, Esteve-pastor MA, Vicente V, Lip GY, Roldán V. Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. Stroke 2019;50:1372-9. [DOI: 10.1161/strokeaha.118.024305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 6] [Article Influence: 10.3] [Reference Citation Analysis]
253 Vitalis A, Shantsila A, Lip GYH. The Reply. Am J Med 2021;134:e354-5. [PMID: 33962715 DOI: 10.1016/j.amjmed.2020.11.033] [Reference Citation Analysis]
254 Sgreccia D, Manicardi M, Malavasi VL, Vitolo M, Valenti AC, Proietti M, Lip GYH, Boriani G. Comparing Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis of 81,462 Patients. J Clin Med 2021;10:3979. [PMID: 34501434 DOI: 10.3390/jcm10173979] [Reference Citation Analysis]
255 Elias A, Morgenstern Y, Braun E, Brenner B, Tzoran I. Direct oral anticoagulants versus enoxaparin in patients with atrial fibrillation and active cancer. Eur J Intern Med 2021;89:132-4. [PMID: 33985888 DOI: 10.1016/j.ejim.2021.04.002] [Reference Citation Analysis]
256 Perreault S, Dragomir A, Côté R, Lenglet A, White-Guay B, de Denus S, Schnitzer ME, Dubé MP, Brophy JM, Dorais M, Tardif JC. Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. Pharmacotherapy 2021;41:379-93. [PMID: 33544915 DOI: 10.1002/phar.2509] [Reference Citation Analysis]
257 Lee SR, Choi EK, Lee SY, Lee E, Han KD, Cha MJ, Kwon WY, Shin SD, Oh S, Lip GYH. Temporal Trends of Emergency Department Visits of Patients with Atrial Fibrillation: A Nationwide Population-Based Study. J Clin Med 2020;9:E1485. [PMID: 32423155 DOI: 10.3390/jcm9051485] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
258 Boriani G, Vitolo M, Diemberger I, Proietti M, Valenti AC, Malavasi VL, Lip GYH. Optimizing indices of AF susceptibility and burden to evaluate AF severity, risk and outcomes. Cardiovasc Res 2021:cvab147. [PMID: 33913486 DOI: 10.1093/cvr/cvab147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
259 López-Gálvez R, Marín F, Rivera-Caravaca JM. Predicting heart failure in atrial fibrillation patients: What about using biomarkers? Am Heart J 2022;251:32-4. [PMID: 35537504 DOI: 10.1016/j.ahj.2022.05.007] [Reference Citation Analysis]
260 Krittayaphong R, Phrommintikul A, Winijkul A, Methavigul K, Komoltri C, Kaewkumdee P, Yindeengam A; COOL-AF Investigators. Influence of gender on the clinical outcomes of Asian non-valvular atrial fibrillation patients: insights from the prospective multicentre COOL-AF registry. BMJ Open 2021;11:e043862. [PMID: 33958338 DOI: 10.1136/bmjopen-2020-043862] [Reference Citation Analysis]
261 Naranjo L, Ostos F, Gil-Etayo FJ, Hernández-Gallego J, Cabrera-Marante Ó, Pleguezuelo DE, Díaz-Simón R, Cerro M, Lora D, Martínez-Salio A, Serrano A. Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke. Front Cardiovasc Med 2021;8:665741. [PMID: 34012984 DOI: 10.3389/fcvm.2021.665741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
262 King PK, Fosnight SM, Bishop JR. Consensus Clinical Decision-Making Factors Driving Anticoagulation in Atrial Fibrillation. Am J Cardiol 2019;124:1038-43. [PMID: 31375243 DOI: 10.1016/j.amjcard.2019.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
263 Pahlmeyer L, Huang J. Monitoring of rivaroxaban levels in patients with class III obesity. Am J Health Syst Pharm 2020;77:1013-7. [PMID: 32382756 DOI: 10.1093/ajhp/zxaa096] [Reference Citation Analysis]
264 Kwon S, Kim TJ, Choi EK, Ahn HJ, Lee E, Lee SR, Ko SB, Oh S, Lip GYH. Predictors of ischemic stroke for low-risk patients with atrial fibrillation: A matched case-control study. Heart Rhythm 2021;18:702-8. [PMID: 33482386 DOI: 10.1016/j.hrthm.2021.01.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Bawazeer GA, Alkofide HA, Alsharafi AA, Babakr NO, Altorkistani AM, Kashour TS, Miligkos M, AlFaleh KM, Al-Ansary LA. Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias. Cochrane Database Syst Rev 2021;10:CD013504. [PMID: 34674223 DOI: 10.1002/14651858.CD013504.pub2] [Reference Citation Analysis]
266 Park S, Je NK. Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants. Int J Arrhythm 2022;23. [DOI: 10.1186/s42444-021-00053-9] [Reference Citation Analysis]
267 Rivera-Caravaca JM, Marín F, Esteve-Pastor MA, Gálvez J, Lip GYH, Vicente V, Roldán V. Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. BMJ Open 2019;9:e033712. [PMID: 31843852 DOI: 10.1136/bmjopen-2019-033712] [Reference Citation Analysis]
268 Ding WY, Gupta D, Wong CF, Lip GYH. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovasc Res 2021;117:1046-59. [PMID: 32871005 DOI: 10.1093/cvr/cvaa258] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
269 Camelo-castillo A, Rivera-caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V. Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. Thromb Haemost 2020;120:1200-7. [DOI: 10.1055/s-0040-1712914] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
270 Choi SY, Kim MH, Lee KM, Cho YR, Park JS, Kim SW, Kim JK, Chung M, Yun SC, Lip GYH. Anticoagulant Therapy in Initially Low-Risk Patients With Nonvalvular Atrial Fibrillation Who Develop Risk Factors. J Am Heart Assoc 2020;9:e016271. [PMID: 32779499 DOI: 10.1161/JAHA.120.016271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
271 Kaewsaengeak C, Pienputtarapong U, Tocharoenchok T. The effectiveness of split tablet dosing versus alternate-day dosing of warfarin: a randomized control trial. Sci Rep 2021;11:24060. [PMID: 34912021 DOI: 10.1038/s41598-021-03606-z] [Reference Citation Analysis]
272 Ghosh S, Krege W, Doerr B, Mischnik M, Pragst I, Dickneite G, Herzog E. Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models. PLoS One 2021;16:e0258192. [PMID: 34614035 DOI: 10.1371/journal.pone.0258192] [Reference Citation Analysis]
273 Park J, Lee SR, Choi EK, Kwon S, Jung JH, Han KD, Cha MJ, Ko SB, Oh S, Lip GYH. Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation. J Clin Med 2019;8:E2228. [PMID: 31861095 DOI: 10.3390/jcm8122228] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
274 Lip GY, Ruff CT, Moores L. Response. Chest 2019;155:1309. [DOI: 10.1016/j.chest.2019.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
275 Wolfe RC, Evans T. Antithrombotic Therapy and Regional Anesthesia. J Perianesth Nurs 2019;34:439-46. [PMID: 30914136 DOI: 10.1016/j.jopan.2019.01.001] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
276 Farinha JM, Jones ID, Lip GYH. Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation. European Heart Journal Supplements 2022;24:A42-55. [DOI: 10.1093/eurheartj/suab152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
277 Liang JB, Lao CK, Tian L, Yang YY, Wu HM, Tong HH, Chan A. Impact of a pharmacist-led education and follow-up service on anticoagulation control and safety outcomes at a tertiary hospital in China: a randomised controlled trial. Int J Pharm Pract 2020;28:97-106. [PMID: 31576625 DOI: 10.1111/ijpp.12584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
278 Krittayaphong R, Chichareon P, Komoltri C, Kornbongkotmas S, Yindeengam A, Lip GYH. Low Body Weight Increases the Risk of Ischemic Stroke and Major Bleeding in Atrial Fibrillation: The COOL-AF Registry. J Clin Med 2020;9:E2713. [PMID: 32842610 DOI: 10.3390/jcm9092713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
279 Liu F, Wang Y, Luo J, Huang L, Zhu W, Yin K, Xue Z. Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four post-hoc Analyses of Randomized Clinical Trials. Front Cardiovasc Med 2022;9:841341. [DOI: 10.3389/fcvm.2022.841341] [Reference Citation Analysis]
280 Komatsu Y, Yokoyama S, Hosomi K, Takada M. Impact of Medication Adherence on the Association Between Oral Anticoagulant Use and Risk of Dementia: A Retrospective Cohort Study using the Japanese Claims Database. Drugs Real World Outcomes 2022. [PMID: 35717555 DOI: 10.1007/s40801-022-00311-9] [Reference Citation Analysis]
281 Lowres N, Giskes K, Hespe C, Freedman B. Reducing Stroke Risk in Atrial Fibrillation: Adherence to Guidelines Has Improved, but Patient Persistence with Anticoagulant Therapy Remains Suboptimal. Korean Circ J 2019;49:883-907. [PMID: 31535493 DOI: 10.4070/kcj.2019.0234] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
282 Levy JH, Connors JM, Steiner ME, Douketis J, Spyropoulos AC. Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. Res Pract Thromb Haemost 2020;4:562-8. [PMID: 32548554 DOI: 10.1002/rth2.12320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
283 Rivera-Caravaca JM, Roldán V, Vicente V, Lip GYH, Marín F. Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. Mayo Clin Proc 2020;95:2360-9. [PMID: 33153628 DOI: 10.1016/j.mayocp.2020.05.046] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
284 Nattel S, Lip GYH. Guideline Implications of Prothrombotic State Assessment in Low-Risk Atrial Fibrillation Patients: Consistency With CHA2DS2-VASc and Support for CHADS-65. Can J Cardiol 2019;35:547-9. [PMID: 31030855 DOI: 10.1016/j.cjca.2019.03.001] [Reference Citation Analysis]
285 Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, Yan L, Xing Y, Shi H, Li S, Liu Y, Liu F, Feng M, Chen Y, Lip GYH; MAFA II Investigators. Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. J Am Coll Cardiol 2019;74:2365-75. [PMID: 31487545 DOI: 10.1016/j.jacc.2019.08.019] [Cited by in Crossref: 117] [Cited by in F6Publishing: 88] [Article Influence: 39.0] [Reference Citation Analysis]
286 Stevens VM, Trujillo T, Mueller SW, MacLaren R, Reynolds PM, Kiser TH. Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center. Clin Appl Thromb Hemost 2019;25:1076029619896619. [PMID: 31876159 DOI: 10.1177/1076029619896619] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
287 Corica B, Romiti GF, Raparelli V, Cangemi R, Basili S, Proietti M. Epidemiology of cerebral microbleeds and risk of adverse outcomes in atrial fibrillation: a systematic review and meta-analysis. Europace 2022:euac028. [PMID: 35244694 DOI: 10.1093/europace/euac028] [Reference Citation Analysis]
288 Kotalczyk A, Ding WY, Wong CF, Rao A, Gupta D, Lip GYH. Atrial Fibrillation in Patients with Chronic Kidney Disease. Cardiol Clin 2021;39:435-46. [PMID: 34247756 DOI: 10.1016/j.ccl.2021.04.005] [Reference Citation Analysis]
289 Bentley R, Hardy LJ, Scott LJ, Sharma P, Philippou H, Lip GYH. Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation. Expert Opin Investig Drugs 2021;:1-13. [PMID: 33682570 DOI: 10.1080/13543784.2021.1897786] [Reference Citation Analysis]
290 Fan Y, Zhang G, Zhang Z, Zhang S, Lin M, Lin Y, Huang Y, Zhong X, Zhuang X, Liao X. Critical Appraisal of Guidelines for Antithrombotic Therapy in Atrial Fibrillation Post-Percutaneous Coronary Intervention. gh 2022;17:14. [DOI: 10.5334/gh.1104] [Reference Citation Analysis]
291 Krittayaphong R, Pumprueg S, Thongsri T, Wiwatworapan W, Choochunklin T, Kaewkumdee P, Yindeengam A; COOL-AF Investigators. Impact of anemia on clinical outcomes of patients with atrial fibrillation: The COOL-AF registry. Clin Cardiol 2021;44:415-23. [PMID: 33538035 DOI: 10.1002/clc.23559] [Reference Citation Analysis]
292 Pasea L, Chung SC, Pujades-Rodriguez M, Shah AD, Alvarez-Madrazo S, Allan V, Teo JT, Bean D, Sofat R, Dobson R, Banerjee A, Patel RS, Timmis A, Denaxas S, Hemingway H. Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis. BMC Med 2019;17:206. [PMID: 31744503 DOI: 10.1186/s12916-019-1438-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
293 Lane DA, Lip GYH. Integrated care for the management of atrial fibrillation: what are the key components and important outcomes? EP Europace 2019;21:1759-61. [DOI: 10.1093/europace/euz211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
294 Mongkhon P, Naser AY, Fanning L, Tse G, Lau WC, Wong IC, Kongkaew C. Oral anticoagulants and risk of dementia: A systematic review and meta-analysis of observational studies and randomized controlled trials. Neuroscience & Biobehavioral Reviews 2019;96:1-9. [DOI: 10.1016/j.neubiorev.2018.10.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
295 Lip GYH, Ruff CT, Moores L; 2018 CHEST guideline Expert Panel. Response. Chest 2019;155:1307. [PMID: 31174649 DOI: 10.1016/j.chest.2019.02.329] [Reference Citation Analysis]
296 Lane DA, Dagres N, Dan GA, García Seara J, Iliodromitis K, Lenarczyk R, Lip GYH, Mansourati J, Marín F, Scherr D, Potpara TS. Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. Europace 2019;21:1116-25. [PMID: 30874724 DOI: 10.1093/europace/euz033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
297 Obeidat M, Burgess M, Lip GY. Atrial Fibrillation in Heart Failure. Cardiology Clinics 2022;40:245-58. [DOI: 10.1016/j.ccl.2021.12.012] [Reference Citation Analysis]
298 Mohamed AA, Alnewais ME, Ibrahim YA, Zaitoun MF. Pharmacists' warfarin therapy knowledge and counseling practices in the Eastern Province, Saudi Arabia: A cross-sectional study. J Pharm Bioallied Sci 2020;12:289-94. [PMID: 33100789 DOI: 10.4103/jpbs.JPBS_233_19] [Reference Citation Analysis]
299 Proietti M, Lane DA, Boriani G, Lip GY. Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. Canadian Journal of Cardiology 2019;35:619-33. [DOI: 10.1016/j.cjca.2019.02.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
300 Vitolo M, Proietti M, Shantsila A, Boriani G, Lip GYH. Clinical Phenotype Classification of Atrial Fibrillation Patients Using Cluster Analysis and Associations with Trial-Adjudicated Outcomes. Biomedicines 2021;9:843. [PMID: 34356907 DOI: 10.3390/biomedicines9070843] [Reference Citation Analysis]
301 Chao TF, Nedeljkovic MA, Lip GYH, Potpara TS. Stroke prevention in atrial fibrillation: comparison of recent international guidelines. Eur Heart J Suppl 2020;22:O53-60. [PMID: 33380944 DOI: 10.1093/eurheartj/suaa180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
302 Peled H, Dau NQ, Lau H. Key Points to Consider When Evaluating Andexxa for Formulary Addition. Neurocrit Care 2020;33:20-4. [DOI: 10.1007/s12028-019-00866-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
303 Romiti GF, Pastori D, Rivera-Caravaca JM, Ding WY, Gue YX, Menichelli D, Gumprecht J, Kozieł M, Yang PS, Guo Y, Lip GYH, Proietti M. Adherence to the 'Atrial Fibrillation Better Care' Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients. Thromb Haemost 2021. [PMID: 34020488 DOI: 10.1055/a-1515-9630] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
304 Meyer-Junco L. Time to Deprescribe: A Time-Centric Model for Deprescribing at End of Life. J Palliat Med 2021;24:273-84. [PMID: 33226878 DOI: 10.1089/jpm.2020.0430] [Reference Citation Analysis]
305 Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, Martinez-Calle N, Parry-Jones N, Patten PEM, Schuh A, Walewska R; BSH guidelines committee, UK CLL Forum. Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Br J Haematol 2022;196:70-8. [PMID: 34498258 DOI: 10.1111/bjh.17788] [Reference Citation Analysis]
306 Sim V, Galbraith K. Effectiveness of multimedia interventions in the provision of patient education on anticoagulation therapy: A review. Patient Educ Couns 2020;103:2009-17. [PMID: 32532633 DOI: 10.1016/j.pec.2020.05.003] [Reference Citation Analysis]
307 Andrade JG, Mitchell LB. Periprocedural Anticoagulation for Cardioversion of Acute Onset Atrial Fibrillation and Flutter: Evidence Base for Current Guidelines. Canadian Journal of Cardiology 2019;35:1301-10. [DOI: 10.1016/j.cjca.2019.06.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
308 Huisman BAA, Geijteman ECT, Kolf N, Dees MK, van Zuylen L, Szadek KM, Steegers MAH, van der Heide A. Physicians' Opinions on Anticoagulant Therapy in Patients with a Limited Life Expectancy. Semin Thromb Hemost 2021;47:735-44. [PMID: 33971680 DOI: 10.1055/s-0041-1725115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Lip GYH, Bhatt DL, Hohnloser SH, Kimura T, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Cannon CP. Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range. J Am Coll Cardiol 2019;74:2431-3. [PMID: 31699285 DOI: 10.1016/j.jacc.2019.09.009] [Reference Citation Analysis]
310 Lee CJ, Toft-Petersen AP, Ozenne B, Phelps M, Olesen JB, Ellinor PT, Gislason G, Lip GYH, Torp-Pedersen C, Gerds TA. Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach. Eur Heart J Cardiovasc Pharmacother 2021;7:f3-f10. [PMID: 32531029 DOI: 10.1093/ehjcvp/pvaa063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
311 Ding WY, Harrison SL, Lane DA, Lip GYH. Considerations when choosing an appropriate bleeding risk assessment tool for patients with atrial fibrillation. J Thromb Haemost 2020;18:788-90. [DOI: 10.1111/jth.14738] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
312 Cohen AT, Lewis M, Connor A, Connolly SJ, Yue P, Curnutte J, Alikhan R, Maccallum P, Tan J, Green L. Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding. JACEP Open 2022;3. [DOI: 10.1002/emp2.12655] [Reference Citation Analysis]
313 Meador S, Dyke S, Togami J, Kuskov B, Burnett AE. Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics. J Thromb Thrombolysis 2021. [PMID: 34410560 DOI: 10.1007/s11239-021-02551-y] [Reference Citation Analysis]
314 An J, Bider Z, Luong TQ, Cheetham TC, Lang DT, Fischer H, Reynolds K. Long-Term Medication Adherence Trajectories to Direct Oral Anticoagulants and Clinical Outcomes in Patients With Atrial Fibrillation. J Am Heart Assoc 2021;10:e021601. [PMID: 34713708 DOI: 10.1161/JAHA.121.021601] [Reference Citation Analysis]
315 Lee HF, Chan YH, Li PR, Liu JR, Chao TF, Wu LS, Chang SH, Yeh YH, Kuo CT, See LC, Lip GYH. Oral Anticoagulants and Antiplatelet Agents in Patients With Atrial Fibrillation and Concomitant Critical Limb Ischemia: A Nationwide Cohort Study. Can J Cardiol 2021;37:113-21. [PMID: 32492401 DOI: 10.1016/j.cjca.2020.02.071] [Reference Citation Analysis]
316 Lip GYH. The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. Int J Clin Pract 2019;73:e13285. [DOI: 10.1111/ijcp.13285] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
317 Krittayaphong R, Winijkul A, Methavigul K, Sairat P, investigators COOLF, De Luca L. The Rate of Clinical Outcomes in Atrial Fibrillation according to Antithrombotic Strategy: The COOL-AF Registry. Cardiovascular Therapeutics 2022;2022:1-10. [DOI: 10.1155/2022/5797257] [Reference Citation Analysis]
318 Lip GYH, Gue Y, Zhang J, Chao TF, Calkins H, Potpara T. Stroke Prevention in Atrial Fibrillation. Trends Cardiovasc Med 2021:S1050-1738(21)00113-4. [PMID: 34619337 DOI: 10.1016/j.tcm.2021.10.001] [Reference Citation Analysis]
319 Harrison SL, Akpan A, Lip GYH. Frailty and cognitive impairment are not reasons to withhold anticoagulation in people with atrial fibrillation but screening could guide management. J Am Geriatr Soc 2021;69:1807-10. [PMID: 33893638 DOI: 10.1111/jgs.17142] [Reference Citation Analysis]
320 Ibarra F Jr. Review of Prothrombin Complex Concentrates Use in Apixaban and Rivaroxaban Associated Intracranial Hemorrhages. J Pharm Pract 2021;:8971900211015059. [PMID: 34036837 DOI: 10.1177/08971900211015059] [Reference Citation Analysis]
321 Choi SY, Kim MH, Kim HB, Kang SY, Lee KM, Hyun K, Yun S. Validation of the CHA2DS2-VA Score (Excluding Female Sex) in Nonvalvular Atrial Fibrillation Patients: A Nationwide Population-Based Study. JCM 2022;11:1823. [DOI: 10.3390/jcm11071823] [Reference Citation Analysis]
322 Ajabnoor AM, Zghebi SS, Parisi R, Ashcroft DM, Rutter MK, Doran T, Carr MJ, Mamas MA, Kontopantelis E. Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study. PLoS Med 2022;19:e1004003. [PMID: 35671329 DOI: 10.1371/journal.pmed.1004003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
323 Methavigul K, Sairat P, Krittayaphong R; COOL-AF Investigators. Efficacy of R2CHA2DS2-VA score for predicting thromboembolism in Thai patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 2021;21:540. [PMID: 34772351 DOI: 10.1186/s12872-021-02370-2] [Reference Citation Analysis]
324 Blumer V, Rivera M, Corbalán R, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Hellkamp AS, Singer DE, Fox KAA, Patel MR. Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. Am Heart J 2021;236:4-12. [PMID: 33571477 DOI: 10.1016/j.ahj.2021.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
325 Fernández CS, Gullón A, Formiga F. The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation. J Comp Eff Res 2020;9:509-23. [PMID: 32329353 DOI: 10.2217/cer-2019-0197] [Reference Citation Analysis]
326 Wadsworth D, Sullivan E, Jacky T, Sprague T, Feinman H, Kim J. A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. J Clin Pharm Ther 2021;46:560-70. [PMID: 33393699 DOI: 10.1111/jcpt.13343] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
327 Arbel A, Abu‐ful Z, Preis M, Cohen S, Saliba W. Adherence with direct oral anticoagulants in patients with atrial fibrillation: Trends, risk factors, and outcomes. J Arrhythmia. [DOI: 10.1002/joa3.12656] [Reference Citation Analysis]
328 Okutucu S, Görenek B. Perspectives by a position statement on atrial fibrillation in acute heart failure a: Mechanisms and therapeutic approaches. Anatol J Cardiol 2020;23:308-11. [PMID: 32478687 DOI: 10.14744/AnatolJCardiol.2020.17064] [Reference Citation Analysis]
329 Best JG, Cardus B, Klijn CJM, Lip G, Seiffge DJ, Smith EE, Werring DJ. Antithrombotic dilemmas in stroke medicine: new data, unsolved challenges. J Neurol Neurosurg Psychiatry 2022:jnnp-2020-325249. [PMID: 35728935 DOI: 10.1136/jnnp-2020-325249] [Reference Citation Analysis]
330 Farkowski MM, Jubele K, Marín F, Gandjbakhch E, Ptaszynski P, Merino JL, Lenarczyk R, Potpara TS. Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey. Europace 2020;22:162-9. [PMID: 31501852 DOI: 10.1093/europace/euz257] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 10.0] [Reference Citation Analysis]
331 Boriani G, Palmisano P, Malavasi VL, Fantecchi E, Vitolo M, Bonini N, Imberti JF, Valenti AC, Schnabel RB, Freedman B. Clinical Factors Associated with Atrial Fibrillation Detection on Single-Time Point Screening Using a Hand-Held Single-Lead ECG Device. J Clin Med 2021;10:729. [PMID: 33673209 DOI: 10.3390/jcm10040729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
332 Qian Y, Zhang J, Li J, Weng Z. A retrospective study on the evaluation of the appropriateness of oral anticoagulant therapy for patients with atrial fibrillation. PLoS One 2021;16:e0259199. [PMID: 34762667 DOI: 10.1371/journal.pone.0259199] [Reference Citation Analysis]
333 Kwon S, Lee SR, Choi EK, Lee E, Jung JH, Han KD, Cha MJ, Oh S, Lip GYH. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Gastrointestinal Bleeding. Stroke 2021;52:511-20. [PMID: 33412904 DOI: 10.1161/STROKEAHA.120.030761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
334 Wang SY, Giugliano RP. Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients. Am J Cardiol 2020;127:176-83. [PMID: 32423697 DOI: 10.1016/j.amjcard.2020.04.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
335 Ding WY, Rivera-Caravaca JM, Marin F, Torp-Pedersen C, Roldán V, Lip GYH. Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS. J Clin Med 2021;10:3357. [PMID: 34362143 DOI: 10.3390/jcm10153357] [Reference Citation Analysis]
336 Proietti M, Rivera-Caravaca JM, Esteve-Pastor MA, Marín F, Lip GYH. Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. Thromb Haemost 2021;121:1107-14. [PMID: 33296920 DOI: 10.1055/a-1333-4448] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
337 Raschi E, Bianchin M, Gatti M, Squizzato A, De Ponti F. Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews. Drug Saf 2019;42:1409-22. [DOI: 10.1007/s40264-019-00866-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
338 Targher G. Risk of atrial fibrillation in patients with nonalcoholic steatohepatitis. Liver Int 2019;39:818-20. [PMID: 31020773 DOI: 10.1111/liv.14049] [Reference Citation Analysis]
339 Zhou Y, Dai Y, Lu L, Fu Z. Dabigatran-induced esophagitis: A case report. Medicine (Baltimore) 2020;99:e19890. [PMID: 32332662 DOI: 10.1097/MD.0000000000019890] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
340 Gorenek (Chair) B, Halvorsen S, Kudaiberdieva G, Bueno H, Van Gelder IC, Lettino M, Marin F, Masip J, Mueller C, Okutucu S, Poess J, Potpara TS, Price S, Lip (Co-chair) GY. Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. European Heart Journal: Acute Cardiovascular Care 2020;9:348-57. [DOI: 10.1177/2048872619894255] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
341 Fauchier L, Boriani G, de Groot JR, Kreutz R, Rossing P, Camm AJ. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace 2021;23:1873-91. [PMID: 34411235 DOI: 10.1093/europace/euab184] [Reference Citation Analysis]
342 Valencia D, Spoutz P, Stoppi J, Kibert JL 2nd, Allen A, Parra D, Hough A. Impact of a Direct Oral Anticoagulant Population Management Tool on Anticoagulation Therapy Monitoring in Clinical Practice. Ann Pharmacother 2019;53:806-11. [PMID: 30854862 DOI: 10.1177/1060028019835843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
343 Kaide CG, Gulseth MP. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents. The Journal of Emergency Medicine 2020;58:217-33. [DOI: 10.1016/j.jemermed.2019.10.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
344 Lip GYH, Keshishian AV, Kang AL, Dhamane AD, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Garcia Reeves AB, Yuce H, Deitelzweig S. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J Intern Med 2021;289:42-52. [PMID: 32602228 DOI: 10.1111/joim.13140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
345 Kozieł M, Simovic S, Pavlovic N, Nedeljkovic M, Kocijancic A, Paparisto V, Music L, Trendafilova E, Dan AR, Manola S, Kusljugic Z, Dan GA, Lip GYH, Potpara TS; BALKAN‐AF Investigators. Treatment implications of renal disease in patients with atrial fibrillation: The BALKAN-AF survey. J Arrhythm 2020;36:863-73. [PMID: 33024464 DOI: 10.1002/joa3.12404] [Reference Citation Analysis]
346 Kotalczyk A, Kalarus Z, Wright DJ, Boriani G, Lip GYH. Cardiac Electronic Devices: Future Directions and Challenges. Med Devices (Auckl) 2020;13:325-38. [PMID: 33061681 DOI: 10.2147/MDER.S245625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
347 Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GY, Oldgren J, ten Berg JM, Cannon CP; on behalf of the REDUAL PCI Steering Committee and Investigators. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. Circ: Cardiovascular Interventions 2020;13. [DOI: 10.1161/circinterventions.119.008349] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
348 Lip GYH, Tran G, Genaidy A, Marroquin P, Estes C, Landsheftl J. Improving dynamic stroke risk prediction in non-anticoagulated patients with and without atrial fibrillation: Comparing common clinical risk scores and machine learning algorithms. Eur Heart J Qual Care Clin Outcomes 2021:qcab037. [PMID: 33999139 DOI: 10.1093/ehjqcco/qcab037] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
349 Ritchie LA, Lane DA, Lip GYH. Worldwide trends in antithrombotic therapy prescribing for atrial fibrillation: observations on the 'transition era' to non-vitamin K antagonist oral anticoagulants. Europace 2021:euab313. [PMID: 34964471 DOI: 10.1093/europace/euab313] [Reference Citation Analysis]
350 Williams DS, Mikhova K, Sodhi S. Arrhythmias and Pregnancy: Management of Preexisting and New-Onset Maternal Arrhythmias. Cardiol Clin 2021;39:67-75. [PMID: 33222815 DOI: 10.1016/j.ccl.2020.09.013] [Reference Citation Analysis]
351 Vorobyeva NM, Tkacheva ON. The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? Racionalʹnaâ farmakoterapiâ v kardiologii 2020;16:984-93. [DOI: 10.20996/1819-6446-2020-12-03] [Reference Citation Analysis]
352 Esteve-Pastor MA, Rivera-Caravaca JM, Ruiz-Ortiz M, Muñiz J, Roldán-Rabadán I, Otero D, López-Gálvez R, Cequier Á, Bertomeu-Martínez V, Badimón L, Anguita M, Lip GYH, Marín F; FANTASIIA investigators. A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: Effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry. Expert Opin Pharmacother 2022. [PMID: 35924672 DOI: 10.1080/14656566.2022.2109961] [Reference Citation Analysis]
353 López-Sendón JL, Alonso-Rodríguez D, Barón-Esquivias G, Cosin-Sales J, Marín F, Galera-Llorca J, Jiménez N, Marler S, Huisman MV, Lip GYH; Spanish GLORIA-AF investigators. Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program. Med Clin (Barc) 2021:S0025-7753(21)00605-9. [PMID: 34895750 DOI: 10.1016/j.medcli.2021.09.016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
354 John RM, Sharma D. Contraindication to Anticoagulation in Nonvalvular Atrial Fibrillation: Are We Still to Fear the Clot and Not the Bleed? JACC Clin Electrophysiol 2019;5:1393-5. [PMID: 31857037 DOI: 10.1016/j.jacep.2019.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
355 Sylvester KW, Chen A, Lewin A, Fanikos J, Goldhaber SZ, Connors JM. Optimization of DOAC management services in a centralized anticoagulation clinic. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
356 Smith MN, Deloney L, Carter C, Weant KA, Eriksson EA. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. J Thromb Thrombolysis 2019;48:250-5. [DOI: 10.1007/s11239-019-01846-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 15.0] [Reference Citation Analysis]
357 Patti G, Haas S. Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. J Cardiovasc Pharmacol 2020;77:11-21. [PMID: 33060545 DOI: 10.1097/FJC.0000000000000927] [Reference Citation Analysis]
358 Kwon S, Jung JH, Choi EK, Lee SW, Park J, Lee SR, Kang J, Han K, Park KW, Oh S, Lip GYH. Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Korean Circ J 2021;51:409-22. [PMID: 33764010 DOI: 10.4070/kcj.2020.0407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
359 Ding WY, Harrison S, Gupta D, Lip GYH, Lane DA. Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. Front Med (Lausanne) 2020;7:54. [PMID: 32154260 DOI: 10.3389/fmed.2020.00054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
360 Bawazeer GA, Alkofide H, Alsharafi A, Babakr N, Altorkistani A, Kashour T, Miligkos M, Alfaleh K, Al-ansary LA; Cochrane Heart Group. Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013504] [Reference Citation Analysis]
361 Ording AG, Søgaard M, Skjøth F, Grove EL, Lip GYH, Larsen TB, Nielsen PB. Hematuria in anticoagulated patients with atrial fibrillation and urologic cancer. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12629] [Reference Citation Analysis]
362 Haymart B, Barnes GD, Kong X, Ali M, Kline-Rogers E, DeCamillo D, Kaatz S. Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline Recommendations. JAMA Netw Open 2022;5:e2222089. [PMID: 35834255 DOI: 10.1001/jamanetworkopen.2022.22089] [Reference Citation Analysis]
363 Kozieł M, Mazurek M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Brandes A, Paquette M, Zint K, França LR, Lu S, Bartels DB, Huisman MV, Lip GYH. Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. J Clin Med 2020;9:E1969. [PMID: 32586056 DOI: 10.3390/jcm9061969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
364 Camelo-Castillo A, Rivera-Caravaca JM, Orenes-Piñero E, Ramírez-Macías I, Roldán V, Lip GYH, Marín F. Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. J Clin Med 2021;10:715. [PMID: 33670220 DOI: 10.3390/jcm10040715] [Reference Citation Analysis]
365 Harrison SL, Lane DA, Lip GYH. Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes. Eur J Heart Fail 2020;22:136-8. [PMID: 31820530 DOI: 10.1002/ejhf.1685] [Reference Citation Analysis]
366 Wattanaruengchai P, Nathisuwan S, Karaketklang K, Wongcharoen W, Phrommintikul A, Lip GYH. Comparison of the HAS-BLED versus ORBIT scores in predicting major bleeding among Asians receiving direct-acting oral anticoagulants. Br J Clin Pharmacol 2021. [PMID: 34783372 DOI: 10.1111/bcp.15145] [Reference Citation Analysis]
367 Boriani G, Colella J, Imberti J, Fantecchi E, Vitolo M. Female sex and stroke in atrial fibrillation: an intriguing relationship. Intern Emerg Med 2020;15:175-9. [DOI: 10.1007/s11739-019-02169-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
368 Boriani G, Lee G, Parrini I, Lopez-Fernandez T, Lyon AR, Suter T, Van der Meer P, Cardinale D, Lancellotti P, Zamorano JL, Bax JJ, Asteggiano R; Council of Cardio-Oncology of the European Society of Cardiology. Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. Eur J Prev Cardiol 2021;28:611-21. [PMID: 33624005 DOI: 10.1093/eurjpc/zwaa054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
369 Kozieł M, Merino JL, De Caterina R, Huber K, Jin J, Melino M, Goette A, Lip GYH; ENSURE-AF Investigators. Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. Eur J Clin Invest 2020;50:e13221. [PMID: 32150758 DOI: 10.1111/eci.13221] [Reference Citation Analysis]
370 Guo Y, Lane DA, Wang L, Zhang H, Wang H, Zhang W, Wen J, Xing Y, Wu F, Xia Y, Liu T, Wu F, Liang Z, Liu F, Zhao Y, Li R, Li X, Zhang L, Guo J, Burnside G, Chen Y, Lip GYH; mAF-App II Trial Investigators. Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. J Am Coll Cardiol 2020;75:1523-34. [PMID: 32241367 DOI: 10.1016/j.jacc.2020.01.052] [Cited by in Crossref: 78] [Cited by in F6Publishing: 61] [Article Influence: 39.0] [Reference Citation Analysis]
371 Shyamkumar K, Hirsh J, Bhagirath VC, Ginsberg JS, Eikelboom JW, Chan NC. Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable? TH Open 2021;5:e84-8. [PMID: 33655194 DOI: 10.1055/s-0040-1721734] [Reference Citation Analysis]
372 Tsai CT, Liao JN, Chiang CE, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chao TF, Lip GYH, Chen SA. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage. JAMA Netw Open 2020;3:e206424. [PMID: 32478848 DOI: 10.1001/jamanetworkopen.2020.6424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
373 Gorog DA, Gue YX, Chao TF, Fauchier L, Ferreiro JL, Huber K, Konstantinidis SV, Lane DA, Marin F, Oldgren J, Potpara T, Roldan V, Rubboli A, Sibbing D, Tse HF, Vilahur G, Lip GYH. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace 2022:euac020. [PMID: 35323922 DOI: 10.1093/europace/euac020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
374 Shantsila A, Shantsila E, Lip GYH. Blood pressure targets in atrial fibrillation. Eur Heart J 2020;41:2860-2. [PMID: 32460328 DOI: 10.1093/eurheartj/ehaa319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
375 Goette A, Auricchio A, Boriani G, Braunschweig F, Terradellas JB, Burri H, Camm AJ, Crijns H, Dagres N, Deharo J, Dobrev D, Hatala R, Hindricks G, Hohnloser SH, Leclercq C, Lewalter T, Lip GYH, Merino JL, Mont L, Prinzen F, Proclemer A, Pürerfellner H, Savelieva I, Schilling R, Steffel J, van Gelder IC, Zeppenfeld K, Zupan I, Heidbüchel H, Boveda S, Defaye P, Brignole M, Chun J, Guerra Ramos JM, Fauchier L, Svendsen JH, Traykov VB, Heinzel FR; ESC Scientific Document Group. EHRA White Paper: knowledge gaps in arrhythmia management—status 2019. EP Europace 2019;21:993-4. [DOI: 10.1093/europace/euz055] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
376 Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Di Fusco M, Garcia Reeves AB, Yuce H, Lip GYH. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. J Am Geriatr Soc 2019;67:1662-71. [PMID: 31112292 DOI: 10.1111/jgs.15956] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
377 Zeymer U, Bonnemeier H, Wanner C. [Safety and effectiveness of oral anticoagulation in patients with atrial fibrillation and renal insufficiency - a real-world perspective]. Dtsch Med Wochenschr 2022;147:617-24. [PMID: 35545071 DOI: 10.1055/a-1792-7094] [Reference Citation Analysis]
378 Chew D, Piccini JP. Long-term oral anticoagulant after catheter ablation for atrial fibrillation. Europace 2021:euaa365. [PMID: 33400774 DOI: 10.1093/europace/euaa365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
379 Lacoste JL, Hansen CL. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting. Am J Health Syst Pharm 2019;76:1395-402. [PMID: 31505555 DOI: 10.1093/ajhp/zxz152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
380 Xu J, Jiang G, Zhang L, Chen Z, Wang H, Bai M, Zeng J. Successful percutaneous left atrial appendage occlusion for atrial fibrillation in a patient with mirror-image dextrocardia: a case report. BMC Cardiovasc Disord 2022;22. [DOI: 10.1186/s12872-021-02369-9] [Reference Citation Analysis]
381 Gawałko M, Lodziński P, Budnik M, Tymińska A, Wancerz A, Ozierański K, Kapłon-Cieślicka A, Grabowski M, Opolski G, Lenarczyk R, Kalarus Z, Lip GYH, Balsam P. Vascular disease in patients with atrial fibrillation. A report from Polish participants in the EORP-AF General Long-Term Registry. Int J Clin Pract 2021;75:e13701. [PMID: 32915461 DOI: 10.1111/ijcp.13701] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
382 Cemin R, Foco L, Zoccali C, De Caterina R. Should We Continue Assessing Glomerular Filtration Rate with the Cockroft-Gault Formula in NOAC-Treated Patients? The Magnitude of the Problem. J Clin Med 2020;9:E1893. [PMID: 32560421 DOI: 10.3390/jcm9061893] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
383 Chen N, Gabriel N, Brooks MM, Hernandez I. Joint Latent Class Analysis of Oral Anticoagulation Use and Risk of Stroke or Systemic Thromboembolism in Patients with Atrial Fibrillation. Am J Cardiovasc Drugs 2021;21:573-80. [PMID: 33844177 DOI: 10.1007/s40256-021-00476-8] [Reference Citation Analysis]
384 Warden BA, Diep C, Ran R, Thomas M, Cigarroa JE. The effect of heparin infusion intensity on outcomes for bridging hospitalized patients with atrial fibrillation. Clin Cardiol 2019;42:995-1002. [PMID: 31483512 DOI: 10.1002/clc.23256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
385 Choi SY, Kim MH, Lee KM, Cho Y, Park JS, Yun S, Lip GYH. Age-Dependent Anticoagulant Therapy for Atrial Fibrillation Patients with Intermediate Risk of Ischemic Stroke: A Nationwide Population-Based Study. Thromb Haemost 2021;121:1151-60. [DOI: 10.1055/a-1336-0476] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
386 Hsu JY, Liu PP, Liu AB, Lin SM, Huang HK, Loh CH. Lower Risk of Dementia in Patients With Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Population-Based Cohort Study. J Am Heart Assoc 2021;10:e016437. [PMID: 33586465 DOI: 10.1161/JAHA.120.016437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
387 Truong L, Whitfield K, Nickerson-Troy J, Francoforte K. Drive-thru anticoagulation clinic: Can we supersize your care today? J Am Pharm Assoc (2003) 2021;61:e65-7. [PMID: 33214058 DOI: 10.1016/j.japh.2020.10.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
388 Salmasi S, Safari A, Kapanen A, Adelakun A, Kwan L, MacGillivray J, Andrade JG, Deyell MW, Loewen P. Oral anticoagulant adherence and switching in patients with atrial fibrillation: A prospective observational study. Res Social Adm Pharm 2022:S1551-7411(22)00180-2. [PMID: 35753963 DOI: 10.1016/j.sapharm.2022.06.002] [Reference Citation Analysis]
389 King CS, Freiheit E, Brown AW, Shlobin OA, Aryal S, Ahmad K, Khangoora V, Flaherty KR, Venuto D, Nathan SD. Association Between Anticoagulation and Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Patient Registry. Chest 2021;159:1507-16. [PMID: 33075376 DOI: 10.1016/j.chest.2020.10.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
390 Lisman T, Caldwell SH, Intagliata NM. Haemostatic alterations and management of haemostasis in patients with cirrhosis. J Hepatol 2022;76:1291-305. [PMID: 35589251 DOI: 10.1016/j.jhep.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Camporese G, Bernardi D, Bernardi E, Avruscio GP, Marchini F, Bonfante L, Furian L, Neri F, Villalta S, Fabris F, Simioni P, Sartori MT. Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. Vascul Pharmacol 2020;130:106682. [PMID: 32438078 DOI: 10.1016/j.vph.2020.106682] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
392 Perreault S, Dragomir A, Côté R, Lenglet A, de Denus S, Dorais M, White-Guay B, Brophy J, Schnitzer ME, Dubé MP, Tardif JC. Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation. Front Pharmacol 2021;12:812018. [PMID: 35095525 DOI: 10.3389/fphar.2021.812018] [Reference Citation Analysis]
393 Lane DA, Lip GYH. Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal. Eur Heart J Suppl 2020;22:O14-27. [PMID: 33380941 DOI: 10.1093/eurheartj/suaa178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
394 Kim K, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN, Lee MH, Lip GYH, Joung B. Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: A nationwide cohort study. Am Heart J 2021;242:123-31. [PMID: 34480879 DOI: 10.1016/j.ahj.2021.08.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
395 Scheibner AC, Franco-Martinez C, Kincaide E, Hall R, Long C. The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. Prog Transplant 2021;31:236-41. [PMID: 34155947 DOI: 10.1177/15269248211024601] [Reference Citation Analysis]
396 Domek M, Gumprecht J, Mazurek M, Chao TF, Lip GYH. Should We Judge Stroke Risk by Static or Dynamic Risk Scores? A Focus on the Dynamic Nature of Stroke and Bleeding Risks in Patients With Atrial Fibrillation. J Cardiovasc Pharmacol 2019;74:491-8. [PMID: 31599783 DOI: 10.1097/FJC.0000000000000750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
397 Lee HF, See LC, Li PR, Liu JR, Chao TF, Chang SH, Wu LS, Yeh YH, Kuo CT, Chan YH, Lip GYH. Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease. Eur Heart J Cardiovasc Pharmacother 2021;7:50-8. [PMID: 31778146 DOI: 10.1093/ehjcvp/pvz072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
398 Samaras A, Kartas A, Akrivos E, Fotos G, Dividis G, Vasdeki D, Vrana E, Rampidis G, Karvounis H, Giannakoulas G, Tzikas A. A novel prognostic tool to predict mortality in patients with atrial fibrillation: The BASIC-AF risk score. Hellenic J Cardiol 2021:S1109-9666(21)00007-5. [PMID: 33524615 DOI: 10.1016/j.hjc.2021.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
399 . Use of SAMe-TT₂R₂ Score to Predict the Quality of Anticoagulation Control in Patients with Atrial Fibrillation Receiving Warfarin in Thailand. J Med Assoc Thai 2020;103:548-52. [DOI: 10.35755/jmedassocthai.2020.06.10827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
400 Arbelo E, Aktaa S, Bollmann A, D'Avila A, Drossart I, Dwight J, Hills MT, Hindricks G, Kusumoto FM, Lane DA, Lau DH, Lettino M, Lip GYH, Lobban T, Pak HN, Potpara T, Saenz LC, Van Gelder IC, Varosy P, Gale CP, Dagres N, Boveda S, Deneke T, Defaye P, Conte G, Lenarczyk R, Providencia R, Guerra JM, Takahashi Y, Pisani C, Nava S, Sarkozy A, Glotzer TV, Martins Oliveira M; (Chair)., (Co-chair)., Reviewers., (review coordinator). Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace 2021;23:494-5. [PMID: 32860039 DOI: 10.1093/europace/euaa253] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
401 Shantsila A, Oxborough D, Fairbairn TA, Lip GYH. Clinical factors and imaging leading to risk of incident atrial fibrillation. Eur Heart J Cardiovasc Imaging 2019;20:988-9. [PMID: 31356655 DOI: 10.1093/ehjci/jez199] [Reference Citation Analysis]
402 Matyushkin AV. [Features of the course and therapeutic aspects of deep vein thrombosis in elderly and senile patients]. Khirurgiia (Mosk) 2022;:133-9. [PMID: 35658145 DOI: 10.17116/hirurgia2022061133] [Reference Citation Analysis]
403 Guo Y, Lip GYH, Lane DA. Lifestyle and risk factor modification for reduction of atrial fibrillation: We could do more. Trends Cardiovasc Med 2020;30:387-8. [PMID: 32276083 DOI: 10.1016/j.tcm.2020.03.007] [Reference Citation Analysis]
404 Gusdon AM, Farrokh S, Grotta JC. Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. Semin Neurol 2021. [PMID: 33851394 DOI: 10.1055/s-0041-1726331] [Reference Citation Analysis]
405 Ryu R, Tran R. DOACs in Mechanical and Bioprosthetic Heart Valves: A Narrative Review of Emerging Data and Future Directions. Clin Appl Thromb Hemost 2022;28:10760296221103578. [PMID: 35642259 DOI: 10.1177/10760296221103578] [Reference Citation Analysis]
406 Gross PL, Chan NC. Thromboembolism in Older Adults. Front Med (Lausanne) 2020;7:470016. [PMID: 33585495 DOI: 10.3389/fmed.2020.470016] [Reference Citation Analysis]
407 Zapata J, Paamoni A, Rinard B, Abdou A, Zimmer D, Letherer CC. The Watchman device for preventing stroke in patients with atrial fibrillation. JAAPA 2021;34:33-8. [PMID: 34582384 DOI: 10.1097/01.JAA.0000769672.18363.3f] [Reference Citation Analysis]
408 Patel IJ, Rahim S, Davidson JC, Hanks SE, Tam AL, Walker TG, Wilkins LR, Sarode R, Weinberg I. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part II: Recommendations. Journal of Vascular and Interventional Radiology 2019;30:1168-1184.e1. [DOI: 10.1016/j.jvir.2019.04.017] [Cited by in Crossref: 92] [Cited by in F6Publishing: 68] [Article Influence: 30.7] [Reference Citation Analysis]
409 Chan YH, Chuang C, Chan CC, Lee HF, Huang YC, Huang YT, Chang SH, Wang CL, Chao TF, Kuo CT, Yeh YH, Chen SA. Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation. Cardiovasc Diabetol 2020;19:30. [PMID: 32156277 DOI: 10.1186/s12933-020-01005-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
410 Yang PS, Sung JH, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Pak HN, Lee MH, Lip GYH, Joung B. The Effect of Integrated Care Management on Dementia in Atrial Fibrillation. J Clin Med 2020;9:E1696. [PMID: 32498299 DOI: 10.3390/jcm9061696] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
411 Jiang J, Gu X, Cheng CD, Li HX, Sun XL, Duan RY, Zhu Y, Sun L, Chen FK, Bao ZY, Zhang Y, Shen JH. The Hospital-Community-Family-Based Telemedicine (HCFT-AF) Program for Integrative Management of Patients With Atrial Fibrillation: Pilot Feasibility Study. JMIR Mhealth Uhealth 2020;8:e22137. [PMID: 33084588 DOI: 10.2196/22137] [Reference Citation Analysis]
412 Hiramori S, Yamashita Y, Morimoto T, Kadota K, Takase T, Kim K, Oi M, Akao M, Kobayashi Y, Toyofuku M, Inoko M, Tada T, Izumi T, Chen PM, Murata K, Tsuyuki Y, Saga S, Nishimoto Y, Sasa T, Matsuda M, Sakamoto J, Kinoshita M, Togi K, Mabuchi H, Takabayashi K, Nakagawa Y, Kato T, Ono K, Ando K, Kimura T; COMMAND VTE Registry Investigators. Optimal quality of vitamin K antagonist therapy in Japanese patients with venous thromboembolism. J Cardiol 2022:S0914-5087(22)00163-0. [PMID: 35882615 DOI: 10.1016/j.jjcc.2022.07.001] [Reference Citation Analysis]
413 Collins P, Lewin A, Vincze Irving N, Sylvester K, Fanikos J, Goldhaber SZ, Connors JM. Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. Crit Pathw Cardiol 2021;20:103-7. [PMID: 33337730 DOI: 10.1097/HPC.0000000000000251] [Reference Citation Analysis]
414 Dobesh PP, Bhatt SH, Trujillo TC, Glaubius K. Antidotes for reversal of direct oral anticoagulants. Pharmacology & Therapeutics 2019;204:107405. [DOI: 10.1016/j.pharmthera.2019.107405] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
415 Tercanlı MF, Olcay AB, Mutlu O, Bilgin C, Hakyemez B. Investigation of the effect of anticoagulant usage in the flow diverter stent treatment of the patient-specific cerebral aneurysm using the Lagrangian coherent structures. J Clin Neurosci 2021;94:86-93. [PMID: 34863468 DOI: 10.1016/j.jocn.2021.10.007] [Reference Citation Analysis]
416 Mishra A, Singh M, Acker WW, Kamboj S, Sporn D, Stapleton D, Kaluski E. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. J Cardiovasc Pharmacol 2019;74:82-90. [PMID: 31306367 DOI: 10.1097/FJC.0000000000000697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
417 Kozieł M, Teutsch C, Halperin JL, Rothman KJ, Diener HC, Ma CS, Marler S, Lu S, Gurusamy VK, Huisman MV, Lip GYH; GLORIA-AF Investigators. Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. PLoS One 2021;16:e0249524. [PMID: 33852611 DOI: 10.1371/journal.pone.0249524] [Reference Citation Analysis]
418 Kotalczyk A, Potpara TS, Lip GYH. How effective is pharmacotherapy for stroke and what more is needed? A focus on atrial fibrillation. Expert Opin Pharmacother 2021;:1-4. [PMID: 34148469 DOI: 10.1080/14656566.2021.1921738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
419 Kietaibl S, Ferrandis R, Godier A, Llau J, Lobo C, Macfarlane AJ, Schlimp CJ, Vandermeulen E, Volk T, von Heymann C, Wolmarans M, Afshari A. Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines. Eur J Anaesthesiol 2022;39:100-32. [PMID: 34980845 DOI: 10.1097/EJA.0000000000001600] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
420 Favaloro EJ, Gilmore G, Bonar R, Dean E, Arunachalam S, Mohammed S, Baker R. Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference. Clin Chem Lab Med 2020;58:1322-31. [PMID: 32126010 DOI: 10.1515/cclm-2019-1160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
421 Stevens VM, Trujillo TC, Kiser TH, MacLaren R, Reynolds PM, Mueller SW. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. Clin Appl Thromb Hemost 2021;27:10760296211039020. [PMID: 34541920 DOI: 10.1177/10760296211039020] [Reference Citation Analysis]
422 Li X, Liu L, Xu B, Xiang Q, Li Y, Zhang P, Wang Y, Xie Q, Mao Y, Cui Y. Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions. Pharmacol Res Perspect 2020;8:e00593. [PMID: 32338459 DOI: 10.1002/prp2.593] [Reference Citation Analysis]
423 Diener HC, Chutinet A, Easton JD, Granger CB, Kleine E, Marquardt L, Meyerhoff J, Zini A, Sacco RL. Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS. Stroke 2021;52:1065-8. [PMID: 33504190 DOI: 10.1161/STROKEAHA.120.031237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
424 Caturano A, Galiero R, Pafundi PC. Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants. Medicina (Kaunas) 2019;55:E617. [PMID: 31547188 DOI: 10.3390/medicina55100617] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
425 Riva N, Meli S, Borg Xuereb C, Vella K, Ageno W, Makris M, Gatt A. Anticoagulation control with the point-of-care INR: A retrospective pre-/post-analysis. Thromb Res 2020;196:21-4. [PMID: 32823171 DOI: 10.1016/j.thromres.2020.07.050] [Reference Citation Analysis]
426 Favaloro EJ, Gilmore G, Bonar R, Dean E, Arunachalam S, Mohammed S, Baker R. Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects. Haemophilia 2020;26:354-62. [PMID: 31962376 DOI: 10.1111/hae.13930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
427 Corsini A, Ferri N, Proietti M, Boriani G. Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. Drugs 2020;80:1065-83. [PMID: 32504376 DOI: 10.1007/s40265-020-01328-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
428 Wojakowski E, Cheruvil C, Hassan A, Holsen MR, Chen L, Rossi M, Wilcox N, Woodruff AE. Albumin and bleed risk in rivaroxaban treated patients. J Thromb Thrombolysis 2020;50:1004-11. [DOI: 10.1007/s11239-020-02092-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
429 Benipal H, Holbrook A, Paterson JM, Douketis J, Foster G, Thabane L. Predictors of oral anticoagulant-associated adverse events in seniors transitioning from hospital to home: a retrospective cohort study protocol. BMJ Open 2020;10:e036537. [PMID: 32963065 DOI: 10.1136/bmjopen-2019-036537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
430 Milling TJ, Refaai MA, Sengupta N. Anticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines. Dig Dis Sci 2021. [PMID: 33403486 DOI: 10.1007/s10620-020-06728-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
431 Kow CS, Sunter W, Bain A, Zaidi STR, Hasan SS. Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide. Am J Cardiovasc Drugs 2020;20:301-9. [PMID: 32458370 DOI: 10.1007/s40256-020-00415-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
432 Bernaitis N, Badrick T, Anoopkumar-Dukie S. The SAMe-TT2R2 score as an indicator of warfarin control for patients with deep vein thrombosis in Queensland, Australia. J Thromb Thrombolysis 2020;50:614-8. [PMID: 32080812 DOI: 10.1007/s11239-020-02068-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
433 Lee SR, Choi EK, Han KD, Jung JH, Cha MJ, Oh S, Lip GYH. Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. Stroke 2019;50:1480-9. [PMID: 31084339 DOI: 10.1161/STROKEAHA.118.024264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
434 Methavigul K, Methavigul R. Use of simplified HAS-BLED score in patients with atrial fibrillation receiving warfarin. J Arrhythm 2019;35:711-5. [PMID: 31624509 DOI: 10.1002/joa3.12225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
435 Wiegmann AL, Khalid SI, Coogan AC, Xu TQ, Decesare LA, Skertich NJ, Velasco J, Myers JA. Antithrombotic prescriptions for many general surgery patients significantly increases the likelihood of post-operative bleeding complications. The American Journal of Surgery 2020;219:453-9. [DOI: 10.1016/j.amjsurg.2019.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
436 Covert K, Branam DL. Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. American Journal of Health-System Pharmacy 2020;77:865-76. [DOI: 10.1093/ajhp/zxaa059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
437 Li G, Lip GY, Marcucci M, Thabane L, Tian J, Levine MA. The number needed to treat for net effect (NNTnet) as a metric for measuring combined benefits and harms. Journal of Clinical Epidemiology 2020;125:100-7. [DOI: 10.1016/j.jclinepi.2020.05.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
438 Han S, Kim YH, Lee MY, Bang OY, Jang SW, Han S, Park YJ, Kang S, On YK, Suh HS. Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study. J Clin Med 2021;10:3918. [PMID: 34501364 DOI: 10.3390/jcm10173918] [Reference Citation Analysis]
439 Yang PS, Sung JH, Jang E, Yu HT, Kim TH, Lip GYH, Joung B. Application of the simple atrial fibrillation better care pathway for integrated care management in frail patients with atrial fibrillation: A nationwide cohort study. J Arrhythm 2020;36:668-77. [PMID: 32782638 DOI: 10.1002/joa3.12364] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
440 Mahmood M, Lip GY. Management of atrial fibrillation: easy as ABC. Minerva Med 2019;110. [DOI: 10.23736/s0026-4806.18.05824-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
441 Reiffel JA. Oral Anticoagulation and Antiarrhythmic Drug Therapy for Atrial Fibrillation. J Innov Card Rhythm Manag 2018;9:3446-52. [PMID: 32494480 DOI: 10.19102/icrm.2018.091201] [Reference Citation Analysis]
442 Jones DW, Minhas S, Fierro JJ, Ardeshna D, Rawal A, Cave B, Shah SP, Khouzam RN. From WOEST to AUGUSTUS: a review of safety and efficacy of triple versus dual antithrombotic regimens in patients with atrial fibrillation requiring percutaneous coronary intervention for acute coronary syndrome. Ann Transl Med 2019;7:405. [PMID: 31660304 DOI: 10.21037/atm.2019.08.21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
443 Krittayaphong R, Chantrarat T, Rojjarekampai R, Jittham P, Sairat P, Lip GYH. Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry. J Clin Med 2020;9:E1698. [PMID: 32498302 DOI: 10.3390/jcm9061698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
444 Noviyani R, Youngkong S, Nathisuwan S, Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, McKay G, Sritara P, Attia J, Thakkinstian A. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evid Based Med 2021:bmjebm-2020-111634. [PMID: 34635480 DOI: 10.1136/bmjebm-2020-111634] [Reference Citation Analysis]
445 Wang H, Liu T, Li Q, Cui R, Fan X, Tong Y, Ma S, Liu C, Zhang J. NSAID Treatment Before and on the Early Onset of Acute Kidney Injury Had an Opposite Effect on the Outcome of Patients With AKI. Front Pharmacol 2022;13:843210. [PMID: 35656310 DOI: 10.3389/fphar.2022.843210] [Reference Citation Analysis]
446 Nielsen PB, Milling TJ, Lip GYH. Intracerebral Hemorrhage and Exposure to Antithrombotic Drugs. JAMA Netw Open 2021;4:e219175. [PMID: 33950212 DOI: 10.1001/jamanetworkopen.2021.9175] [Reference Citation Analysis]
447 Lip GYH, Ruff CT, Moores L; 2018 CHEST Guideline Expert Panel. Response. Chest 2019;155:1311-2. [PMID: 31174653 DOI: 10.1016/j.chest.2019.03.037] [Reference Citation Analysis]
448 Steensig K, Pareek M, Krarup AL, Sogaard P, Maeng M, Tayal B, Lee CJ, Torp-pedersen C, Lip GY, Holland-fischer P, Kragholm KH. Thromboembolism and bleeding in patients with atrial fibrillation and liver disease – a nationwide register-based cohort study. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101952] [Reference Citation Analysis]
449 Ntaios G, Huisman MV, Diener HC, Halperin JL, Teutsch C, Marler S, Gurusamy VK, Thompson M, Lip GYH, Olshansky B; GLORIA-AF Investigators. Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. Hellenic J Cardiol 2021;62:152-7. [PMID: 33338644 DOI: 10.1016/j.hjc.2020.11.009] [Reference Citation Analysis]
450 Kotalczyk A, Lip GY, Calkins H. The 2020 ESC Guidelines on the Diagnosis and Management of Atrial Fibrillation. Arrhythm Electrophysiol Rev 2021;10:65-7. [PMID: 34401177 DOI: 10.15420/aer.2021.07] [Reference Citation Analysis]
451 Antoniou C, Manolakou P, Arsenos P, Dilaveris P, Gatzoulis K, Tousoulis D. Antithrombotic Treatment after Atrial Fibrillation Ablation. CPD 2020;26:2703-14. [DOI: 10.2174/1381612826666200407154329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
452 Ding Y, Niu J, Fan J, Liu Y. Repeated mechanical thrombectomy for acute ischemic stroke in a dialysis patient: A case report and literature review. Hemodialysis International 2019;24. [DOI: 10.1111/hdi.12811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
453 Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, Fauchier L, Betts TR, Lewalter T, Saw J, Tzikas A, Sternik L, Nietlispach F, Berti S, Sievert H, Bertog S, Meier B, Lenarczyk R, Nielsen-kudsk JE, Tilz R, Kalarus Z, Boveda S, Deneke T, Heinzel FR, Landmesser U, Hildick-smith D; ESC Scientific Document Group. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update. EP Europace 2020;22:184-184. [DOI: 10.1093/europace/euz258] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
454 Abuan I, Wong KH, Bolinske B, Hale KS. Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban. J Pharm Technol 2019;35:119-25. [PMID: 34860981 DOI: 10.1177/8755122519839437] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
455 Liss DB, Mullins ME. Antithrombotic and Antiplatelet Drug Toxicity. Crit Care Clin 2021;37:591-604. [PMID: 34053708 DOI: 10.1016/j.ccc.2021.03.012] [Reference Citation Analysis]
456 Gumprecht J, Szulik M, Domek M, Mazurek M, Shantsila A, Oxborough D, Lip GYH. Novel Echocardiographic Biomarkers in the Management of Atrial Fibrillation. Curr Cardiovasc Imaging Rep 2019;12. [DOI: 10.1007/s12410-019-9520-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
457 Phrommintikul A, Nathisuwan S, Gunaparn S, Krittayaphong R, Wongcharoen W, Sehmi S, Mehta S, Winkles N, Brocklehurst P, Mathers J, Jowett S, Jolly K, Lane D, Thomas GN, Lip GYH; TREATS-AF Study Group. Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TT2R2 score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): a study protocol. BMJ Open 2021;11:e051987. [PMID: 34635526 DOI: 10.1136/bmjopen-2021-051987] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
458 Sagris D, Leventis I, Georgiopoulos G, Korompoki E, Makaritsis K, Vemmos K, Milionis H, Lip GYH, Ntaios G. Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. Eur J Intern Med 2020;79:31-6. [PMID: 32409203 DOI: 10.1016/j.ejim.2020.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
459 Pritchett RV, Clarke JL, Jolly K, Clarkesmith D, Bem D, Turner GM, Thomas GN, Lane DA. Clinicians' views and experiences of prescribing oral anticoagulants for stroke prevention in atrial fibrillation: A qualitative meta-synthesis. PLoS One 2020;15:e0232484. [PMID: 32379847 DOI: 10.1371/journal.pone.0232484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
460 Narasimhan B, Aedma SK, Bhatia K, Garg J, Kanuri SH, Turagam MK, Lakkireddy D. Current practice and future prospects in left atrial appendage occlusion. Pacing Clin Electrophysiol 2021;44:1236-52. [PMID: 34085712 DOI: 10.1111/pace.14284] [Reference Citation Analysis]
461 Eckman MH, Wise R, Knochelmann C, Mardis R, Wright S, Gummadi A, Dixon E, Becker R, Schauer DP, Flaherty ML, Costea A, Kleindorfer D, Ireton R, Baker P, Harnett BM, Adejare A, Leonard AC, Sucharew H, Costanzo A, Arduser L, Kues J. Electronic health record-embedded decision support to reduce stroke risk in patients with atrial fibrillation - Study protocol. Am Heart J 2022;247:42-54. [PMID: 35081360 DOI: 10.1016/j.ahj.2022.01.012] [Reference Citation Analysis]
462 Park J, Choi EK, Han KD, Choi YJ, Lee SR, Cha MJ, Kang J, Park KW, Oh S, Lip GYH. Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention During 2-Year Follow-Up, from a Nationwide Population Study. Am J Cardiol 2019;123:1921-6. [PMID: 30967291 DOI: 10.1016/j.amjcard.2019.03.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
463 Davis E, Darais D, Fuji K, Nekola P, Bashir K. Prescribing and Safety of Direct-Acting Oral Anticoagulants Compared to Warfarin in Patients with Atrial Fibrillation on Chronic Hemodialysis. Pharmacy (Basel) 2020;8:E37. [PMID: 32164234 DOI: 10.3390/pharmacy8010037] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
464 Mitchell A, Watson MC, Welsh T, McGrogan A. Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists for People Aged 75 Years and over with Atrial Fibrillation: A Systematic Review and Meta-Analyses of Observational Studies. J Clin Med 2019;8:E554. [PMID: 31022899 DOI: 10.3390/jcm8040554] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
465 Amirtabar A, Vazquez SR, Saunders J, Witt DM. Antiplatelet therapy indication in patients also prescribed direct oral anticoagulants. J Thromb Thrombolysis 2022. [PMID: 35442003 DOI: 10.1007/s11239-021-02602-4] [Reference Citation Analysis]
466 May JE, Moll S. How I treat unexplained arterial thrombosis. Blood 2020;136:1487-98. [PMID: 32584955 DOI: 10.1182/blood.2019000820] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
467 Onundarson PT, Flygenring B. Oral anticoagulant monitoring: Are we on the right track? Int J Lab Hematol 2019;41 Suppl 1:40-8. [PMID: 31069986 DOI: 10.1111/ijlh.13008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
468 Guo Y, Lane DA, Chen Y, Lip GY. Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. The American Journal of Medicine 2020;133:1195-1202.e2. [DOI: 10.1016/j.amjmed.2020.03.019] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 27.0] [Reference Citation Analysis]
469 Cascone AE, Daley MJ, Pan N, Padilla-Tolentino E, Milling TJ. Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor-Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage. Pharmacotherapy 2021;41:501-7. [PMID: 33866591 DOI: 10.1002/phar.2525] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
470 Boriani G, Proietti M. Screening for atrial fibrillation: Need for an integrated, structured approach. European Journal of Internal Medicine 2019;67:33-5. [DOI: 10.1016/j.ejim.2019.07.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
471 Turakhia M, Sundaram V, Smith SN, Ding V, Michael Ho P, Kowey PR, Piccini JP, Foody J, Birmingham MC, Ianus J, Rajmane A, Mahaffey KW; smartADHERE Investigators. Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial. Am Heart J 2021;237:68-78. [PMID: 33676886 DOI: 10.1016/j.ahj.2021.02.023] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Epling JW Jr, Kubik M, Li L, Ogedegbe G, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB; US Preventive Services Task Force. Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement. JAMA 2022;327:360-7. [PMID: 35076659 DOI: 10.1001/jama.2021.23732] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
473 Barrios V, Escobar C, Prieto L, Polo J, Muñiz J, Anguita M, H Lip GY. A new index to predict quality of anticoagulation control in patients on vitamin K antagonists: the DAFNE score. Future Cardiol 2021;17:685-92. [PMID: 33331173 DOI: 10.2217/fca-2020-0122] [Reference Citation Analysis]
474 Denfeld QE, Turrise S, MacLaughlin EJ, Chang PS, Clair WK, Lewis EF, Forman DE, Goodlin SJ; American Heart Association Cardiovascular Disease in Older Populations Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; and Stroke Council. Preventing and Managing Falls in Adults With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circ Cardiovasc Qual Outcomes 2022;15:e000108. [PMID: 35587567 DOI: 10.1161/HCQ.0000000000000108] [Reference Citation Analysis]
475 Del-Toro-Cervera J, Demelo-Rodriguez P, Galeano-Valle F, Fidalgo Á, Sampériz Á, Muñoz-Torrero JFS, Lima J, Sigüenza P, Tufano A, Monreal M; RIETE Investigators. Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE registry. Thromb Res 2020;194:178-82. [PMID: 32788113 DOI: 10.1016/j.thromres.2020.06.022] [Reference Citation Analysis]
476 Obi AT, Thompson JR, Beaulieu RJ, Sutzko DC, Osborne N, Albright J, Gallagher KA, Henke PK. Bleeding and thrombotic outcomes associated with postoperative use of direct oral anticoagulants after open peripheral artery bypass procedures. J Vasc Surg 2020;72:1996-2005.e4. [PMID: 32278573 DOI: 10.1016/j.jvs.2020.02.021] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
477 Lee SR, Choi EK, Kwon S, Han KD, Jung JH, Cha MJ, Oh S, Lip GYH. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation. Stroke. 2019;50:2245-2249. [PMID: 31208303 DOI: 10.1161/strokeaha.119.025536] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 10.3] [Reference Citation Analysis]